Loop-Mediated Isothermal Amplification as Point-of-Care Diagnosis for Neglected Parasitic Infections

Catalina Avendaño and Manuel Alfonso Patarroyo

1 Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A.), Bogotá 111166, Colombia; cavendano@udca.edu.co
2 Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá 111321, Colombia
3 Basic Sciences Department, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá 112111, Colombia

* Correspondence: mapatarr.fidic@gmail.com; Tel.: +57-1-3244672

Received: 2 September 2020; Accepted: 7 October 2020; Published: 28 October 2020

Abstract: The World Health Organisation (WHO) has placed twenty diseases into a group known as neglected tropical diseases (NTDs), twelve of them being parasitic diseases: Chagas’ disease, cysticercosis/taeniasis, echinococcosis, food-borne trematodiasis, human African trypanosomiasis (sleeping sickness), leishmaniasis, lymphatic filariasis, onchocerciasis (river blindness), schistosomiasis, soil-transmitted helminthiasis (ascariasis, hookworm, trichuriasis), guinea-worm and scabies. Such diseases affect millions of people in developing countries where one of the main problems concerning the control of these diseases is diagnosis-based due to the most affected areas usually being far from laboratories having suitable infrastructure and/or being equipped with sophisticated equipment. Advances have been made during the last two decades regarding standardising and introducing techniques enabling diagnoses to be made in remote places, i.e., the loop-mediated isothermal amplification (LAMP) technique. This technique’s advantages include being able to perform it using simple equipment, diagnosis made directly in the field, low cost of each test and the technique’s high specificity. Using this technique could thus contribute toward neglected parasite infection (NPI) control and eradication programmes. This review describes the advances made to date regarding LAMP tests, as it has been found that even though several studies have been conducted concerning most NPI, information is scarce for others.

Keywords: neglected parasitic infection; diagnostic test; LAMP; sensitivity

1. Introduction

Neglected tropical diseases (NTD) can usually be taken as an indicator of extreme poverty. Although this rarely happens, NTD can occur in non-endemic areas, mainly in immigrants and travellers. The most prevalent NTDs causing higher morbidity and mortality include schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma and soil-transmitted helminths; these chronic infections affect at least one billion people, with many more at risk [1].

NTDs are grouped into parasitic, viral and bacterial infections in Africa, Asia and America [2]. The World Health Organisation (WHO) has identified twenty NTDs (Buruli ulcer, Chagas’ disease, cysticercosis/taeniasis, dengue fever, dracunculiasis (guinea worm disease), echinococcosis, food-borne trematodiasis, human African trypanosomiasis (HAT) (sleeping sickness), leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis (river blindness), rabies, schistosomiasis, soil-transmitted helminthiasis (STH) (ascariasis, hookworm, trichuriasis), trachoma, and yaws) [3]. Eleven of these are
considered the most imperative, i.e., Chagas’ disease, food-borne trematodiasis, HAT, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, schistosomiasis, STH and trachoma [2].

One of the main problems concerning NTD is that parasites once considered endemically stable are now moving; for example, it has been reported recently that Schistosoma larvae are infecting humans in Europe. Seasonal migration, extreme weather and disasters and the changes known as the “Great Acceleration” produced by the population’s rapid growth, urbanisation, habitat loss and fragmentation and loss of diversity have led to population movement across borders [4]. Climate change and global warming are increasing the probability and dissemination of many vector-transmitted diseases, including malaria, dengue, Chagas’ disease, leishmaniasis, filariasis, onchocerciasis, schistosomiasis and trypanosomiasis [3].

The 70th World Health Assembly (WHA) adopted a resolution in 2017 regarding a Global Vector Control Response for 2017–2030, whose objective was to prevent, detect, report and respond to outbreaks of vector-transmitted diseases worldwide via an integrated and exhaustive approach [3]. Preventative chemotherapy and transmission control are the two main NTD intervention methods [2]. Great advances have been made during the last decade regarding chemotherapy; however, the same cannot be said about diagnostic tools such as guidelines for chemotherapy and surveillance, mostly due to the lack of a commercially viable market for NTD diagnosis [5].

Diagnostic tests are necessary for monitoring and certifying neglected parasitic infection (NPI) elimination (except for Guinea worm having unmistakable clinical characteristics) [5]. The lack of clear diagnostic strategies has limited obtaining disease surveillance data; diagnostic tools having sufficient sensitivity and specificity for detecting infection levels which could lead to transmission are thus an essential requirement for eliminating or eradicating NPI [5]. Nucleic acid amplification is one of the most valuable tools in all fields of the life sciences, including its use orientated towards fields such as clinical medicine where the diagnosis of infectious diseases, genetic disorders and genetic traits can benefit from using this technique [6].

Polymerase chain reaction (PCR) has been extensively developed for amplifying genes since the beginning of the 1980s. PCR involves extracting nucleic acids from samples, amplification and gene detection; these steps require expensive tools, equipment and installations, thereby hampering test performance [7]. An amplification method known as loop-mediated isothermal amplification (LAMP) reaction has been developed for overcoming such limitations; this test combines speed, simplicity, high specificity and high sensitivity since LAMP’s detection limit reaches up to few copies of DNA compared to PCR. It requires less specialised equipment and infrastructure [6–8].

Based on the above, this review describes the state of the art concerning LAMP, a technique which has been developed for facilitating diagnosis in the field of parasites which the WHO has classified within the NTD group (except for Guinea-worm whose characteristics rule out the use of this technique). The information is presented through tables showing the genes used for designing the primers, samples used for standardising the tests and their detection limit (sensitivity).

2. Loop-Mediated Isothermal Amplification (LAMP)

The fundamental principle of the LAMP method developed by Notomi et al., and patented by Eiken Chemical Co., Ltd. [8], concerns the production of a large amount of DNA amplification products having a mutually complementary sequence and alternate and repeated structure. Four specific primers are used for amplification, recognising a total of six distinct sequences on target DNA: a pair of internal primers (FIP (forward inner primer), BIP (backward inner primer)) and a pair of external ones (F3, B3). The internal primers provide amplification having much greater specificity than that observed using other methods [7]. All four primers are used during the reaction’s initial stages and then just the internal primers are used for strand displacement DNA synthesis [6]. Amplification is carried out at 60–65 °C for 1 hour; nevertheless, amplification speed can be accelerated by using two Loop primers (LF (loop forward) and LB (loop backward)) [8]. This reduces the time needed for increasing and
reducing incubation temperature, finishing faster than general PCR as thermal cycles are not required, thereby enabling simple isothermal equipment to be used, i.e., heat block and water bath [8].

The amplified products can be visualised by agarose gel electrophoresis or detecting turbidity based on magnesium pyrophosphate precipitation, which can be detected by the naked eye or detecting fluorescence by incorporating calcein AM dye which, accompanied by pyrophosphate ion production, triggers a reaction visible by ultraviolet light [8]. The reaction between magnesium ions and calcein AM involves a change in colour from orange to green, which can be seen by the naked eye in natural light. SYBR green I can be used instead of calcein AM. Calcein-based end-point detection is used more frequently due to its great sensitivity and notable change in colour for naked-eye observation [9].

In addition to calcein, colorimetric detection has also been done with other metal ion indicators, e.g., hydroxy naphthol blue which changes positive sample colour, ranging from violet (purple) to sky blue (blue) [10,11]. Eriochrome Black T combined with magnesium ions produces violet; however, when pyrophosphates are released during the reaction, the magnesium ions become combined with the pyrophosphates, changing colour from violet to sky blue [12]. As violet and sky blue belong to the same range of colours this hampers detecting changes by the naked eye, especially when a sample contains a small amount of the sequence to be amplified. Acid chrome blue K has been tested recently; this produces a change from red to blue if the reaction exceeds the detection limit [13]. Incorporating these indicators into the mix reduces the possibility of aerosol contamination.

Visual detection has also been tested with pH sensitive dyes, e.g., neutral red, phenol red, cresol red and m-Cresol purple colour changes, such as red to yellow (phenol red, cresol red), faint orange to pink (neutral red) or purple to yellow (m-Cresol purple). These dyes function when reaction pH begins at 8.8 and rapidly changes to a lower pH (2–3 pH unit drop) [14].

Along with SYBR green I, malachite green dye has been used as a DNA intercalator where reactions range from colourless (negative) to light blue (positive); such colour change can be visualised with the naked eye and (as it does not interfere with Bst DNA polymerase for DNA synthesis) it can be incorporated into the mix before incubation [15].

Results have also been detected by tracking phosphate ions where (by incorporating thermostable inorganic pyrophosphatase) pyrophosphate (LAMP by-product) is hydrolysed into phosphate ions, which mix and react with acidic molybdate and potassium antimonyl tartrate to form yellow ammonium phosphomolybdate trihydrate. Following ascorbic acid incorporation, the yellow compound becomes reduced to dark molybdenum blue. Negative reactions remain colourless; this option has been tested by using a closed disposable device reducing aerosol contamination due to the large amount of DNA that is produced during the reaction [16].

As analysing results by the naked eye can be somewhat subjective, amplified products can be visualised in the field by using lateral flow tests; these are cheap, easy to use, simple, rapid, light and portable. Lateral flow dipstick tests and lateral flow biosensors have been developed [9]. Lateral flow dipstick tests detect biotin-labelled cDNA that has been hybridised with FITC-labelled DNA [17], whereas lateral flow biosensors are based on nanoparticles [18]. Lateral flow tests have been seen to be superior to other monitoring techniques (colorimetric indicator, gel electrophoresis and turbidity) due to the ease of operating them and their rapid results [9,18].

A fluorometer is required for detecting fluorescence, hampering detecting results by the naked eye; however, portable isothermal fluorometers are already being marketed to enable working in the field, e.g., ESEQuant TS2 (Qiagen) [8], AmpliFire (Agdia) and Genie II (OptiGene). Devices have also been developed enabling images to be captured using smartphones. The detection technique, involving quenching unincorporated amplification signal reporters, together with a smartphone’s image analysis app, enables higher precision detection than that obtained when analysing conventional image intensity. This technique does not require opening sample tubes thereby reducing the chance of cross-contamination by aerosols. The smartphone app detects different fluorophores (FAM, HEX, ROX and CY5) [19]. Work has also been done with fluorescence microplate readers based on optical fibre bundles integrated into a smartphone. This device is compatible with a wide range of wavelengths,
enabling the detection of different dyes [20]. The same principle of fluorescence has been used recently for testing a portable smartphone-based instrument for LAMP assay end-point fluorescence detection on a microfluid chip [21].

Tests have also been performed by treating samples with detergents, such as Triton-X or Sodium dodecyl sulfate (SDS), to improve sensitivity to lyse cells and release DNA into solution [22–24].

Flinders Technology Associates (FTA) cards (Whatman) have been studied/used for sample preparation as a direct sampling tool. Sensitivity results have been comparable to those obtained using purified DNA [25,26]. Extraction techniques using commercial kits and heat-treating samples (boil-and-spin or direct boil) have also been tested. The increased sensitivity associated with heat treatment could be due to faster DNA strand separation resulting in a more efficient LAMP test. Using heat-treated samples without compromising sensitivity eliminates the need for DNA extraction and further shortens the time to having results [27] also reducing the cost of and need for extensive laboratory infrastructure [25].

3. Chagas’ Disease (American Trypanosomiasis)

Chagas’ disease is caused by Trypanosoma cruzi and has been considered, “the most neglected of the neglected diseases.” There are gaps regarding research in this field and the development of diagnosis and treatment approaches/techniques [28]. The parasite’s stages in a mammalian host include trypomastigotes (in the blood stream) and amastigotes (intracellular replicative stage), whilst the stages in the vector (triatomine) include epimastigotes and infective metacyclic trypomastigotes [29]. T. cruzi is found in twenty-one continental Latin American countries from the south of the USA to the north of Argentina and Chile [30]. Although this disease has traditionally been considered endemic in South America’s tropical and sub-tropical areas (due to the migration of infected people to non-endemic countries), it has now become a global concern [28].

The infection passes from an acute to a chronic phase; the symptoms are variable and many may become spontaneously decreased during the acute phase. Appropriate treatment may lead to eradicating the parasite. Around 70% of seropositive people are asymptomatic during the chronic phase, 30% may develop cardiac or digestive problems which can last several years or decades and 2–3% have severe forms which can evolve to sudden death [28]. This parasite is known as a silent killer as chronic fatal heart disease-related consequences occur many years after patients have shown acute symptoms [29].

The parasite can be detected during the acute phase using conventional parasitological techniques such as microscopic observation of thick smears or microhaematocrite, xenodiagnosis and haemoculture as currently used diagnostic strategies are stage-dependent. However, such methods have variable sensitivity since they are operator-dependent, xenodiagnosis and haemoculture are cumbersome and delivering the results could take several weeks [31]. Serological tests are usually used for making a diagnosis since parasitaemia is intermittent and low during the chronic phase; however, the WHO has recommended that at least two tests detecting different antigens should be performed regarding T. cruzi’s antigenic variability; test results must coincide for a conclusive diagnosis [31,32].

The sensitivity of existing T. cruzi diagnostic methods regarding early diagnosis of the disease still needs to be improved; tools incorporating nucleic acid amplification thus become a good option. Molecular amplification by conventional PCR or quantitative PCR (qPCR) has been shown to have greater sensitivity and specificity than classical parasitological techniques [32], although requiring costly equipment and installations. Advances have been made regarding standardising techniques requiring less sophisticated equipment and installations in attempts to overcome such limitations, i.e., LAMP. At the time of writing this review, few biomarkers had been tested for LAMP (Table 1; Table 2), even though its sensitivity had been better than that obtained by other techniques (including PCR amplification), having provided good results regarding samples from naturally-infected patients. Diagnosing Chagas’ disease continues being a priority and needs to be improved.
Table 1. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the loop-mediated isothermal amplification (LAMP) technique as a useful tool for diagnosing Chagas’ disease (American trypanosomiasis) in the definitive host.

| Parasite | Marker | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
|----------|--------|-------------------------------|--------|-------------|-------------|-----------|
| T. cruzi | Satellite nuclear repeat region (231 bp) | Extracted DNA | CL Brenner and DM28 strains | - | CL: 5 fg DM28: 50 fg | [33] |
| T. cruzi | Repetitive satellite DNA sequence | Extracted, spiked and natural DNA | Reference strains belonging to the six Discrete Typing Units (DTUs) and human blood | 33 | Extracted DNA: ≥10^-7 parasite equivalents/mL (0.3 fg) Spiked EDTA blood: 10^-2 parasite equivalents/mL. Spiked heparinised blood: 10^-1 parasite equivalents/mL. | [31] |
| T. cruzi | 18S rRNA | Spiked and natural DNA | Human blood | 27 | 50 parasites/mL | [34] |
| T. cruzi | 18S rRNA | Spiked/natural DNA | Tulahuen strain | - | 100 fg | [35] |
| T. cruzi | 18S rRNA | Spiked DNA | Tulahuen strain | - | 1 fg | [36] |

Table 2. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing Chagas’ disease (American trypanosomiasis) in the vector.

| Parasite | Marker | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
|----------|--------|-------------------------------|--------|-------------|-------------|-----------|
| T. cruzi | 18S rRNA | Spiked/natural DNA | Triatomine bugs | 52 | 100 fg | [35] |

The 18S rRNA sequence/marker has been the most used in attempts at standardising a LAMP which would be useful for T. cruzi diagnosis; however, even being the same authors, primer sets reported differ. Given the identity (83%) between T. cruzi and Leishmania spp., primers previously used for standardising a LAMP for Leishmania spp. have been tested for T. cruzi; nevertheless, Leishmania braziliensis and Trypanosoma rangeli were also detected due to the high identity when evaluating the assay’s specificity, which is why Rivero et al. [34] recommended paying special attention to false positives in those geographical regions in which these parasites prevail. One of the standardised techniques [31] in the material revised for this review involved using a prototype; the primers used were not shown in the publication. This prototype amplified a region different to 18S rRNA, being a repetitive satellite DNA sequence whose analytical sensitive limit was similar to and even greater than the sensitivity shown by qPCR (10^-2 fg extracted DNA: 10^-1 fg spiked blood). This further highlighted the recommendation that samples should be taken in EDTA rather than with heparin, since analytical sensitivity is greater than 0.1 parasite equivalents/mL, rising to detect 0.01 parasite equivalents/mL. Reviewing analytical sensitivity in the pertinent publications, it became apparent that the primers and technique conditions giving the greatest sensitivity were those used by Besuschio et al. [31] who demonstrated that using a commercial kit for extracting the samples had the same sensitivity as boiling and spinning them, thereby reducing sample costs and processing times.

4. Echinococcosis

Echinococcosis is a zoonotic parasitic disease which can be caused by larval cestodes from the family Taeniidae. There are two forms, cystic (hydatidosis) caused by Echinococcus granulosus sensu lato and alveolar echinococcosis caused by E. multilocularis [37]. Echinococcosis is endemic in South America, Western Europe, Russia, the Middle East and China. Its prevalence in America ranges from 20 to 95%. The factors increasing its incidence include agriculture-based subsistence, poor socio-economic conditions, regional climate and unhygienic animal slaughtering practices [38]. The parasite requires two mammalian hosts to complete its life-cycle. The adult parasite is found in canids and the larval stage (hydatid cyst) is located in the viscera of ungulate (hooved) animals, especially sheep, goats and
cattle [39]. Dogs are responsible for transmitting the disease to humans who act as incidental host; transmission between humans has not been reported to date [40].

Its clinical presentation is variable; the disease can remain asymptomatic until the cysts burst or until the amount of cysts creates pressure in the tissues surrounding them, depending on the size, location and amount of cysts [39]. The cysts may be present in any visceral organ, including the kidneys, lungs and/or brain; however, they tend to be located in the liver in 66% of cases due to the venous system of intestinal drainage [40]. Diagnosis is based on case history, clinical findings, serology and imaging. Diagnosis is confirmed by microscope observation of the cysts. An immune response is frequently undetectable as it depends on cyst location and stage, thereby hampering serological diagnosis due to its poor sensitivity [38].

Epidemiological surveillance of definitive and intermediate hosts is necessary for controlling and eradicating the disease. This involves using immunological methods such as enzyme-linked immunosorbent assay for coproantigen detection (coproELISA) and PCR. However, coproELISA can give false positives due to crossed reactions with other *Taenia* infections (including *T. hydatigena* or *T. ovis*) [39] whereas conventional PCR and quantitative real-time PCR (qRT-PCR) require sophisticated, expensive equipment, as well as infrastructure which cannot always be found in developing countries [41].

Biomarkers have been used recently for standardising LAMP to overcome such difficulties (Table 3). Standardised LAMP test sensitivity has been significant so far, even surpassing that of conventional PCR. It should be stressed that such tests can be made in remote rural areas using only a water bath or heat block and that the results can be interpreted by the naked eye [41]. Molecular diagnosis is useful for screening in the field and detecting DNA from eggs in environmental samples as an important step in identifying high-risk contaminated areas and establishing/ascertaining the routes for human infection, thereby enabling control programme progress to be determined [37].

**Table 3.** Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing echinococcosis in the definitive host.

| Parasite             | Gene       | Extracted/spiked/natural DNA | Sample                                                                 | Sample Size | Sensitivity | Reference |
|----------------------|------------|------------------------------|------------------------------------------------------------------------|-------------|-------------|-----------|
| *E. granulosus*      | *cox1*     | All of them                  | Protoscolex/dog faeces/collected from the environment                  | Dog faeces: 5 | 10–100 fg   | [42]      |
| complex              |            |                              |                                                                        | Faeces collected from the environment: 61 |             |           |
| *E. granulosus*      | *nad1*     | Natural DNA                  | Hydatid cysts containing protoscolex and associated germinal layers    | 100         | 10 fg       | [41]      |
| complex              |            |                              |                                                                        |             |             |           |
| *E. granulosus*      | *nad5*     | Extracted and natural DNA    | Protoscolex or eggs                                                    | 60          | 1/50 of a single protoscolex or egg | [43]      |
| complex              |            |                              |                                                                        |             |             |           |
| *E. multilocularis*  | Mitochondrial *nad5* | Extracted/ natural DNA | Protoscolex tissue/dog faeces                                          | 189         | 1 pg        | [44]      |
| *E. granulosus*      | Mitochondrial *nad5* | Extracted and natural DNA    | Isolates and faecal samples from dogs                                 | 190         | 10 pg       | [45]      |
| *E. granulosus*      | Repeat region sequence | Spiked DNA                   | Protoscolex recovered from affected sheep livers                      | -           | 1 pg/200 mg faeces | [46]      |

The articles found and referenced here were all written by different research groups; most of them coincided in using the subunit 1 or 5 of the mitochondrial NADH dehydrogenase sequence. Regarding the *nad1* gene, authors have used B3 and BIP common primers, each one having an additional nucleotide at the 5′ or 3′ extreme of the sequence, whilst all the primers used for *nad5* were different. Differences regarding the units in which the authors expressed analytical sensitivity limit results hampered comparison; nevertheless, it can be stated that greater sensitivity could be obtained (10 fg) with the primers used by Ahmed et al. [41] for amplifying the *nad1* gene; depending
on the *Echinococcus* species being analysed, this sensitivity can be matched also when amplifying a *cox1* fragment (10–100 fg) with the primers selected by Avila et al. [42].

5. Foodborne Trematodiases

Foodborne trematode infections cause more than two million disability-adjusted life years (DALY) or potential years of life lost (PYLL) worldwide every year, causing chronic liver and lung diseases. The WHO has identified four foodborne trematode/fluke genera: *Clonorchis*, *Opisthorchis*, *Fasciola* and *Paragonimus* [47]. At least fifty-six million people worldwide suffer one or more foodborne trematodiases. These parasites become acquired by eating aquatic plants (e.g., *Fasciola hepatica*), crustaceans (e.g., *Paragonimus* spp.) or fish (e.g., *Clonorchis sinensis*) [48]. These parasites’ transmission is restricted to areas where the first and second intermediate hosts coexist and where humans consume raw or pickled food or undercooked fish and other aquatic products [49].

Clonorchiasis or Chinese liver fluke disease is caused by the trematode *C. sinensis*. It was estimated in 2016 that more than fifteen million people worldwide were infected and more than two hundred million people were at risk of contracting the infection [50]. This disease is endemic in East Asian countries (China, Korea, Vietnam, Thailand) and far eastern regions of Russia [51]. This parasite’s life-cycle involves freshwater snails (the first intermediate hosts), freshwater fish and occasionally shrimps (the second intermediate hosts) and human or carnivorous mammals (the definitive hosts) [50]. Humans become infected when they consume undercooked or raw fish or shrimp, at the same time ingesting metacercariae. People infected with *C. sinensis* have a 4.47-fold greater chance of developing cholangiocarcinoma than a healthy person [52]. It is thus classified as a group biocarcinogen by the International Agency of Cancer Research (IACR) [51].

Opisthorchiasis is a disease caused by the trematode *Opisthorchis viverrini* or Southeast Asian liver fluke. It has been estimated that around ten million people are infected in the Lower Mekong Basin (Thailand, Lao PDR, Cambodia, Myanmar and Southern Vietnam) [53]. The first host is a freshwater snail whilst the second host involves several cyprinid fish species [54]. Felines are the most important reservoirs, especially in endemic areas, being responsible for persistence in the environment [53]. The main risk factor concerns consuming raw or undercooked cyprinid fish containing metacercariae [53]. The incidence of cholangiocarcinoma in people over thirty-five years old in Thailand (93.8–317.6 per 100,000 people per year) is the highest in the world, especially in the north-west where the disease is endemic. This disease is thus also classified as a group 1 biocarcinogen by the IACR [54].

Fascioliasis is a zoonotic disease caused by the trematode *Fasciola hepatica*, also known as the common liver fluke or sheep liver fluke. This parasite is the most widely distributed trematode worldwide, having been reported in around eighty-one countries [55]. This difficult-to-control disease affects a wide range of mammals, mainly ruminants, having a significant economic impact, especially in developing countries. Fascioliasis has been associated with food consumption in humans; it has been estimated that more than seventeen million people are infected and 90–170 million people live in endemic areas [56]. *F. hepatica* infection causes hepatomegaly, thickening and dilatation of the bile duct and gall bladder which can lead to cholangitis, cholecystitis and obstruction of the bile duct [57].

Migration of the parasite’s juvenile form can also cause damage to and destruction of the liver parenchyma. *F. hepatica* has been reported on five continents, its prevalence ranging from 0.19% to 100% in sheep and 0.12% to 91% in cattle. Such prevalence causes economic losses, whether arising from liver fibrosis, cirrhosis and/or cancer or reduced fertility or milk production, such losses amounting to 3.2 billion dollars per year according to worldwide calculations [57].

Paragonimiasis or lung fluke disease is caused by trematodes from the genus *Paragonimus*. It is caused by consuming improperly cooked freshwater crustaceans, mostly crabs or crayfish, or eating paratenic hosts. More than fifty *Paragonimus* species have been identified around the world in tropical and subtropical regions, mainly in Asia. Around one million people become infected every year according to WHO data [58] and close to twenty million people in Asia, the Americas and Africa could
be exposed to or at risk of contracting the disease; however, its prevalence is not known exactly [59]. The infection’s prevalence depends on the abundance of the infection in animals and the prevalence of infectious metacercariae in crustacean hosts [60].

Its life-cycle requires at least two intermediate hosts as well as the definitive one; its definitive hosts include several mammals, particularly felines, canines and humans, in which it lives in pairs within a fibrous cyst in the lungs, causing pleurisy and pneumonia/bronchitis [58]. The parasite’s erratic migration pattern means that it could invade the brain or spinal cord, causing symptoms of meningitis and even host death. This disease is considered to be debilitating, as it causes morbidity and can delay socio-economic development [59].

The standard diagnostic test for these trematodes is based on microscope detection of eggs in faeces, bile, duodenal fluids or sputum (regarding *Paragonimus* spp.); however, the morphological similarities of these parasites’ eggs sometimes hampers specific diagnosis [49]. Immunodiagnostic tests (ELISA) have thus been developed for detecting trematode eggs; however, many of them cannot differentiate between past and on-going infection. LAMP tests have thus been standardised for overcoming such difficulty by detecting the parasite in samples from different hosts (Tables 4 and 5). However, few tests have been developed to date, meaning that further efforts are needed for developing techniques which will facilitate specific diagnosis to enable successful treatment and which can contribute towards controlling and preventing these infections.

### Table 4. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing foodborne trematodiases in the definitive host.

| Parasite     | Gene          | Extracted/Spiked/ Natural DNA | Sample                                      | Sample Size | Sensitivity | Reference |
|--------------|---------------|------------------------------|---------------------------------------------|-------------|-------------|-----------|
| *C. sinensis* | *cox1*        | All of them                  | Human stool samples                         | 120         | 1 egg/100 mg of faeces | [61]      |
| *F. hepatica* | IGS           | Spiked DNA                   | Samples collected from infected dog liver and faeces | -           | 1 egg      | [62]      |
| *F. hepatica* | ITS2          | Natural DNA                  | Sheep faeces                                | 15          | 10⁻⁷ ng    | [63]      |
| *F. hepatica* | ITS2          | Natural DNA                  | Sheep and cattle faeces                     | Sheep: 39 Cattle: 25 | 10⁻⁴ ng | [64]      |
| *F. hepatica* | IGS           | Extracted DNA                | Individual worms and eggs                   | Adults: 14 Eggs: 1 | 10⁻⁵ ng | [65]      |
| *O. viverrini* | Microsatellite 6 (OVMS6) | Extracted DNA               | Adult worms                                 | 1 ng        |             | [66]      |
| *O. viverrini* | nad1          | Natural DNA                  | Vietnamese isolate (OvBD1) and samples collected from humans | -           | 10⁻³–10⁻⁴ ng | [67]      |
| *O. viverrini* | ITS1          | Natural DNA                  | Adult worms from experimentally infected hamsters and children’s faeces | 37          | 10⁻³ ng    | [68]      |
| *P. westermani* | Ty3/gypsy-like LTR retrotransposon (Rn1) | Natural DNA | Canine blood | 124 | 2.7 fg | [69]      |
| *P. westermani* (Oriental lung fluke) | ITS2 | Natural DNA | Adult worms from experimentally-infected dogs, eggs from patients’ sputum and pleural fluid | Samples from patients' sputum and pleural fluid: 17 | 10⁻⁸ ng | [70]      |
Table 5. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing foodborne trematodiases in the intermediate host.

| Parasite       | Gene  | Extracted/Spiked/Natural DNA | Sample                                      | Sample Size | Sensitivity | Reference |
|----------------|-------|------------------------------|---------------------------------------------|-------------|-------------|-----------|
| C. sinensis    | cox1  | All of them                  | Metacercariae from naturally-infected freshwater fish | -           | 100 fg of DNA | [61]      |
| C. sinensis    | ITS2  | Natural DNA                  | Freshwater snails, shrimp and freshwater fish | Snails: 497 | 10 fg        | [71]      |
|                |       |                              |                                             | Shrimp: 42  | (0.0002/snip)|           |
|                |       |                              |                                             | Freshwater fish: 33 |            |           |
| F. hepatica    | IGS   | Extracted DNA                | Snails                                       | Cercariae: 1| 10^{-5} ng  | [65]      |
| F. gigantica   |       | Natural DNA                  |                                             |             |             |           |
| O. viverrini   | nad1  | Natural DNA                  | samples collected from fish                  |             | 10^{-3}-10^{-4} ng | [67]      |
| P. westermani  | IGS   | Natural DNA                  | Metacercariae from freshwater crabs and crayfish |             | 10^{-8} ng   | [70]      |

Primers amplifying the IGS and ITS2 sequences have been used for standardising LAMP for *F. hepatica* diagnosis. The same primers for IGS were used in both publications; however, the units in which analytical sensitivity limit were measured differed, thereby hindering comparison. Even though the protocol used was different, the result in both cases had good sensitivity: 1 egg [62] or 10^{-5} ng [65]. The technique’s analytical sensitivity limit when using IGS sequences was better than when using ITS2 sequences. Concerning *O. viverrini*, Le et al. [67] obtained the greatest sensitivity when amplifying the *nad1* gene, proving it to be 100 times more sensitive than PCR. Better sensitivity was apparently obtained when amplifying the ITS2 sequence when comparing two studies published concerning *P. westermani*; however, the samples used in both studies were different, meaning that more tests are needed to firmly state which set of primers and protocol provides a better sensitivity.

6. Human African Trypanosomiasis (Sleeping Sickness)

Human African trypanosomiasis (HAT), also known as sleeping sickness, is transmitted by the tsetse fly (Diptera: genus *Glossina*) and is found exclusively in intertropical Africa. The disease can be caused by two *Trypanosoma brucei* subspecies: *Trypanosoma brucei gambiense* and *Trypanosoma brucei rhodesiense*; each one is transmitted by a different *Glossina* subspecies [72]. *T. brucei gambiense* is the most prevalent subspecies; it is anthropogenic and endemic in central and western Africa whereas *T. brucei rhodesiense* is zoonotic and endemic in the south and east of Africa, sporadically affecting humans [73].

The amount of new chronic cases of HAT caused by *T. b. gambiense* reported from 1999 to 2018 fell from 27,862 to 953, representing a 97% reduction. The amount of new acute HAT cases caused by *T. b. rhodesiense* reported during the same period became reduced by 96%, falling from 619 to 24 cases [74]. The WHO’s goal for 2020 was to eliminate HAT as a public health problem; its indicator was fixed as being the presentation of less than 2000 cases for 2020 [73]. This objective has already been achieved, giving rise to a new objective for 2030, i.e., the total elimination of *T. brucei gambiense* transmission to achieve 0 cases [75].

As treatment is complex and potentially toxic, especially during the late phase, all efforts must be concentrated on obtaining an accurate diagnosis by the demonstration of trypanosomes in any body fluid, usually in the blood and lymph system. Once diagnosis has been made, the second step is to establish the stage of the infection in cerebrospinal fluid (CSF); however, identifying trypanosomes in CSF is not very sensitive and tests for measuring IgM, which are more sensitive, are not widely available. New biomarkers are being studied to improve diagnosis [72]. Much research has been done for standardising molecular diagnosis (Tables 6 and 7); however, as HAT diagnosis is a speciality and the techniques are not common, technical assistance is required and reference/benchmark tests are/must be reviewed by two WHO Collaborating Centres for HAT [76].
| Parasite               | Gene                  | Extracted/Spiked/ | Sample                        | Sample Size | Sensitivity | Reference |
|------------------------|-----------------------|-------------------|-------------------------------|-------------|-------------|-----------|
| *T. brucei brucei*     | RIME                  | Spiked DNA        | GVR35 strain                  | -           | Blood treated with RBC lysis solution: 0.04 trypanosomes/mL. | [22]     |
| *T. brucei gambiense*  | 5.85 ribosomal RNA    | Extracted DNA     | *T. brucei gambiense* DAL 972 isolate | -           | ≥1 fg       | [11]     |
| *T. brucei gambiense*  | TgSGP                 | Spiked and natural DNA | Human blood samples          | -           | ~1 fg (-10 trypanosomes/mL) | [77]     |
| *T. congolense*        | 18S rRNA (*CON2-LAMP*) | Natural DNA       | Cattle blood                  | 420         | ND          | [79]     |
| *T. vivax* x *T. brucei rhodesiense* | SRA                  | Natural DNA       | Cattle blood                  | 295         | ND          | [79]     |
| *T. brucei rhodesiense* | 18S rRNA (*CON2-LAMP*) | Natural DNA       | Human blood and CSF           | 6           | ND          | [80]     |
| *T. brucei gambiense*  | RIME                  | Extracted DNA     | Human blood and CSF           | 181         | ND          | [81]     |
| *T. brucei gambiense*  | RIME                  | Natural DNA       | Human blood                   | 253         | ND          | [82]     |
| *T. congolense*        | 18S rRNA (*CON2-LAMP*) | Natural DNA       | Canine blood                  | 6           | ND          | [83]     |
| *T. vivax* x *T. brucei rhodesiense* | SRA                  | Natural DNA       | Human blood and CSF           | 4           | ND          | [84]     |
| *T. brucei rhodesiense* | RIME                  | Extracted DNA     | *T. b. rhodesiense* IL18S2    | -           | 0.1 fg genomic DNA (0.001 parasite) | [23]     |
| *T. brucei rhodesiense* | RIME                  | Spiked DNA        | Human blood and CSF           | -           | Blood: 10 trypanosomes/mL CSF: 10 trypanosomes/mL | [85]     |
| *T. brucei*            | RIME                  | Extracted/natural DNA | *T. br. rhodesiense* isolate LVH 56, *T. b. gambiense* isolate NW2, human blood and CSF | -           | 0.01 trypanosomes/mL | [86]     |
| *T. brucei gambiense*  | TgSGP                 | Extracted DNA     | Isolate PT41 DNA              | -           | 10 trypanosomes/mL | [87]     |
| *T. brucei rhodesiense* | Pseudo-SRA LAMP       | Mouse blood       | Human blood and CSF           | 128         | ND          | [88]     |
| *Sub-genus Trypomastigom* | RIME                  | Extracted and Natural DNA | Human blood and CSF           | 20          | 0.001 trypanosomes/mL | [89]     |
| *T. brucei gambiense*  | Pseudo-SRA LAMP       | Mouse blood       | Human blood and CSF           | 90          | 0.1 trypanosomes/mL | [90]     |
| *T. brucei*            | SRA                   | Experimentally infected/natural DNA | Mouse blood/human blood and CSF | Human sample 6 | Purified DNA: 10 trypanosomes/mL Heat-treated buffy coat: 0.1 pg (1 trypanosome/mL) | [91]     |
| *T. brucei*            | PFR protein A         | Experimentally infected/extracted DNA | Mouse blood and CSF           | -           | *T. brucei* GUTat3.1: 1 pg | [92]     |

* using heat-treated buffy coat.
Table 7. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing HAT (sleeping sickness) in the vector.

| Parasite                  | Gene          | Extracted/Spiked/Natural DNA | Sample          | Sample Size | Sensitivity | Reference |
|---------------------------|---------------|-----------------------------|-----------------|-------------|-------------|-----------|
| T. brucei                 | RIME-LAMP     | Natural DNA                 | Tsetse flies    | 150         | ND          | [90]      |
| T. brucei gambiense       | TgSGP         | Spiked and natural DNA      | Tsetse fly      | -           | ~1 pg (~10 trypanosomes/mL) | [77] |

It was difficult to compare published protocols regarding T. brucei gambiense since all three publications used different primers and one of them expressed sensitivity in a different unit of measurement; however, it can be stated that the sensitivity reported by Nikolskaia et al. [11] (≥ 1 fg) when amplifying the 5.8S ribosomal RNA-ITS2 sequence and that by Njiru et al. [86] (~1 trypanosome/mL) amplifying the TgSGP gene was extremely good. The technique was evaluated with clinical samples by amplifying the RIME sequence; Mitashi et al. [82] tested a commercial kit’s sensitivity and specificity (Loopamp Trypanosoma brucei kit (Eiken Chemical Co LTD) whilst test sensitivity was greater in a study by Mitashi et al. [82] (87.3% (80.9–91.8% 95% CI) in the first run and 93.0% (87.5–96.1% 95% CI) in the second run than in a study by Mugasa et al. [81] (76.9% (64.8–86.5% 95% CI)), contrary to that found regarding specificity: 92.8% (86.4–96.3% 95% CI) in the first run and 96.4% (91.1–98.6% 95% CI) in the second run and 100% (91.6–100% 95% CI), respectively.

The T. brucei rhodesiense SRA sequence was the most studied. Grab et al. [23] reported the greatest analytical sensitivity; they amplified a longer sequence and called it PSEUDO-SRA. Such modifications to primers made the analytical sensitivity limit when working with extracted DNA rise from 0.1–1.0 pg (1–10 parasites), when amplifying the SRA sequence, to 0.1 fg (0.001 parasite) or less. Incorporating Triton X-100 (0.5% final concentration) into a CSF sample represented a 100 to 1000-fold increase in PSEUDO-SRA LAMP assay analytical sensitivity.

The RIME sequence has been used by the authors [78,79] for screening and identifying T. brucei complex and differentiating T. brucei rhodesiense from T. brucei brucei and T. brucei gambiense. RIME and SRA positive samples were considered T. brucei rhodesiense, whilst if they were SRA negative, they could have been T. brucei brucei or T. brucei gambiense. LAMP sensitivity for this sequence was much greater than that for sensitivity by PCR (0.1 to 1000 trypanosomes/mL) [27].

Standardised protocols have been introduced for determining bovine trypanosomosis prevalence [78,79], finding that LAMP can detect more cases than microscope-detected ones, rising from 2 to 28% or from 9.3 to 41.9% depending on the region being studied.

7. Leishmaniasis

Leishmania is an intracellular parasite which infects phagocytic cells; it is transmitted by more than thirty species of phlebotomine sand-flies. The disease is endemic in ninety-eight countries in which it has been estimated that around 350 million people are susceptible to the disease [91]. Around 900,000 to 1.3 million new cases and 20,000–30,000 deaths occur annually in endemic areas every year [92]. The disease’s dynamics are complex and variable, depending on environmental conditions, the vector’s distribution and biology, the reservoirs involved and economic and social aspects affecting human hosts [93].

The disease’s phenotypes involve visceral (VL), cutaneous (CL) and mucocutaneous (MCL) forms. Leishmania major and Leishmania tropica cause CL in the Middle East and central Asia and the Leishmania braziliensis and Leishmania mexicana complexes in the Americas. VL is caused by the Leishmania infantum, Leishmania chagasi and Leishmania donovani complexes. MCL is a mucocutaneous, chronic and severe infection [91]. Leishmania’s transmission dynamics are complex and variable, depending on environmental conditions, the vector’s distribution and biology, the reservoirs involved and sanitary, social and economic aspects affecting human hosts [93]. Leishmania control has been based on preventing sand-fly bites, eliminating animal reservoirs (if it is zoonotic) and the early detection and effective treatment of cases in humans in the absence of an effective vaccine [93].
difference between VL and CL concerns Leishmania VL-causing species’ tendency to cause systemic disease by invading macrophages in the liver, spleen and bone marrow whilst causing minimum damage to the skin [94].

Diagnostic tools for leishmaniasis can currently be divided into three groups (parasitological, serological and molecular), each having its own advantages and disadvantages [25]. Existing tests must be improved as a means of predicting and avoiding relapses, thereby enabling treatment success to be evaluated. This requires the development of specific tests which can do more than just assessing patients’ clinical recovery, not detecting parasites and confirming cure. Diagnostic tests must thus provide immediate, truthful/accurate and confirmatory diagnosis without requiring a central laboratory [93]. LAMP technique-related biomarkers have been studied which has enabled detecting minimal amounts of parasite (1 parasite/mL) (Tables 8 and 9) at low cost [25], thereby facilitating the identification of asymptomatic individuals and monitoring symptomatic patients’ treatment.

Table 8. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing leishmaniasis in the definitive host.

| Parasite | Gene | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
|----------|------|-----------------------------|--------|-------------|-------------|-----------|
| L. siamensis | 18S ribosomal RNA | Extracted/natural DNA | MON-32A, MHOM/TH/2016/TR/human blood samples | 50 | 10^6 parasites/mL (0.0147 ng/µL) | [95] |
| L. infantum | kDNA | Extracted DNA | MHOM/BR/2011/CO6 | - | 1 fg | [96] |
| L. amazonensis | kDNA | Extracted/ experimentally infected DNA | MCAN/BR/2002/BH401 strains/skin samples from hamsters | - | 10 pg to 100 pg a | [97] |
| L. infantum | K26 | Extracted/spiked/natural DNA | MHOM/BR/74/PP75 strain/human blood samples | 219 | 1 fg DNA | [98] |
| L. major | C91 | Natural DNA | Human tissue material | 81 | 20 fg | [99] |
| L. major | Histone H3 gene | | | | 200 fg | |
| Leishmania spp. | 18S rRNA | Extracted/natural DNA | Cutaneous leishmaniasis-causing strains and direct smears from CL patients’ skin lesions | 50 | 1 × 10^3 equivalent parasites | [100] |
| Leishmania spp. | 18S rRNA | Natural DNA | Human skin biopsies | 2 | 1 parasites/µL | [101] |
| Leishmania spp. | 18S ribosomal DNA | Extracted/natural DNA | Visceral leishmaniasis-causing strains and cutaneous leishmaniasis-causing strains/human blood samples and skin samples | CL: 105 VL:50 | 0.01 to 0.001 parasites/µL 0.0001 parasites/µL a | [102] |
| L. donovani | kDNA | Extracted/natural DNA | L. donovani AG83, L. major ASHK and L. tropica WR 66/3VL: human peripheral blood or bone marrow aspirate PKDL: tissue biopsy | VL: 66 from blood and 15 from bone marrow PKDL: 67 | 1 fg | [103] |
| L. major | 18S ribosomal RNA | Extracted/natural DNA | L. major MHOM/TH/1973/ASKH | - | 0.13 parasites/µL | [104] |
| L. tropica | 18S rRNA | Extracted/natural DNA | L. major MHOM/TH/2011/PG | - | 1 fg | [105] |
| L. major | ITS-1 | Extracted/natural DNA | Reference strains/human blood samples | - | 0.1 parasites; 0.1 pg | [106] |
| L. infantum | kDNA | Natural DNA | Human skin lesions | 31 | ND | [107] |
| L. major | 18S ribosomal RNA | Parasite applied to FTA card/natural DNA | L. major MHOM/1973/ASKH/human tissue material | 122 | 0.01 parasites/µL | [108] |
| L. infantum | kDNA | Extracted/natural DNA | L. infantum MCAN/TH/1995/2011 strains/cutaneous/dog swab | 111 | 1 fg | [109] |
| L. siamensis | 18S ribosomal RNA | Spiked DNA | Human saliva and blood | - | 10^6 parasites/mL | [110] |
| L. infantum | kDNA | Natural DNA | Human blood samples | 87 | 1 parasite/mL | [111] |
Table 8. Cont.

| Parasite Gene Extracted/Spiked/ Natural DNA | Sample                  | Sample Size | Sensitivity | Reference |
|-------------------------------------------|-------------------------|-------------|-------------|-----------|
| Leishmania spp. 185S ribosomal RNA Extracted/natural DNA | VL and CL reference strains | -           | 0.01 parasites | [15]      |
| L. major 18S ribosomal DNA Spiked/natural DNA | Mouse blood/swab samples | 41          | 1 × 10^3 parasites/mL | [111]     |
| L. tropica 18S rRNA Extracted DNA          | L. donovani (MHOM/IN/1996/THAK23), L. infantum L4, L. major 230/119, L. major 159/06 and L. major LV39 | -           | 1.6–160 fg |          |
| L. infantum CPB Extracted/natural DNA      | L. infantum (MHOM/TN/80/SPT1)/canine blood samples | 75          | 50 fg       | [113]     |
| L. donovani kDNA Extracted DNA             | L. donovani AG8 (MHOM/IN/83/AG8)/human blood and bone marrow samples | 117         | 1 fg (0.01 parasites) | [114]     |
| L. donovani kDNA Extracted DNA             | L. donovani (MHOM/IN/80/DD8)/human blood | 185         | 1 fg        | [115]     |
| Leishmania spp. 18S rRNA Extracted/natural DNA | L. donovani strain DD8/human blood and skin biopsies | Blood: 30 biopsies: 17 | 10–100 parasites/mL | [116]     |
| L. donovani kDNA Extracted/natural DNA     | L. donovani (MHOM/IN/06/92/S) | 10          | 1 fg        | [117]     |

a 10 pg of DNA using poly-acrylamide gel to visualise the result and 100 pg for colorimetric detection with SYBR Safe. b No amplification with CL-causing Leishmania species. c No amplification at all with L. guyanensis and L. braziliensis strains. d PKDL: post kala-azar dermal leishmaniasis. e Depending on which Leishmania species were tested and the primer sets used.

Table 9. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing leishmaniasis in the vector.

| Parasite Gene Extracted/Spiked/ Natural DNA | Sample                  | Sample Size | Sensitivity | Reference |
|-------------------------------------------|-------------------------|-------------|-------------|-----------|
| Leishmania spp. 18S RNA Extracted/ natural DNA | Sand flies              | 50          | 0.13 parasites/µL or 10 promastigotes in one sand fly | [100]     |
| L. martiniquensis 18S rRNA Extracted/ natural DNA | Sand flies              | 380         | 0.13 parasites/µL or 10 promastigotes in one sand fly | [104]     |
| L. major 18S rRNA Natural DNA Sand flies | -                       | 10^3–10^6 Promastigotes/100 µL-0.1 parasites | [118]     |
| Leishmania spp. 18S ribosomal RNA Extracted/ natural DNA | Sand flies              | 397         | 0.01 parasites | [15]      |

The 18S ribosomal sequence has been most studied when standardising LAMP for Leishmania spp. being shown to have a detection limit of at least 0.01 parasites for LAMP [15] or 10–100 parasites/mL for RT-LAMP [116]. Testing the protocol described by Nzelu et al. [15], León et al. [100], found that LAMP sensitivity was greater (80%: 60.3–90.0 95% CI) than that by qPCR (78.0%: 64.0–88.5% 95% CI). Adams et al. [102] tested a set of primers for amplifying the kDNA sequence. Even though the detection limit was greater (0.0001 parasites/µL) than the 18S ribosomal limit (0.01–0.001 parasites/µL), primers for kDNA CL-causing Leishmania species could not be amplified; however, greater sensitivity (92.3%: 74.9–99.1 95% CI) and specificity (100%: 85.8–100 95% CI) were found for VL when the technique was used with complete blood, surpassing PCR specificity (91.7%: 73–99% 95% CI), but not its sensitivity (96.1%: 80.1–99.9% 95% CI). Such sensitivity was surpassed in a study by Verma et al. [103], using a set of primers designed by Takagi et al. [117] (96.9% sensitivity: 89.6–99.2% 95% CI). The authors recommended using complete blood and not Buffy coat or PBMC regarding a diagnosis of VL. Good sensitivity has also been demonstrated when using bone marrow aspirate (100%: 79.6–100% 95% CI) [103].
The kDNA sequence has been the most studied regarding *L. infantum*. The sets of primers differed in two of the four articles published; the authors did not show the sets of primers in the remaining two articles. Detection test limit was 1 fg (an equivalent of about 0.1 parasites) [96,108] or 1 parasite in 1 mL blood, i.e., 0.025 parasites per reaction [110], this being greater than that found when using K26 [98], 18S ribosomal [112] or CPB sequences [113]. Ghasemian et al. [110] found 93.6% sensitivity (95% CI) and 100% specificity (95% CI) when testing the protocol using VL patients’ blood, having efficacy comparable to that of nested PCR and surpassing the sensitivity found by Adams et al. [102]. The kDNA sequence has been tested with conjunctival swabs from dogs, as well as human blood, for a diagnosis of *L. major* [108], obtaining greater specificity (97%) than that found when canine blood is used for amplifying the CPB sequence (80%: 65.2–89.5 95% CI) [113]. The kDNA sequence has also been most studied for *L. donovani*; regardless of the set of primers used, all have shown a greater detection limit (1 fg (at least 1 parasite) [117] or 0.0001 parasites/µL [102]) than that determined for the 18S ribosomal RNA (30 pg [112]), the detection limit being comparable to the qPCR detection limit. 82.6% sensitivity and 100% specificity have been found when testing primers with skin samples; the authors [106] modified the original protocol for these studies [117].

The 18S ribosomal RNA sequence has been most studied for diagnosing CL (*L. major* and *L. tropica*), detection limits ranging from 0.01 parasites/µL (~1 fg) [107] to 160 fg [112] for *L. major* and 80 fg–3.6 pg [112] for *L. tropica*. Assays have been made for determining the usefulness of FTA cards, using previously described primers [15]; it was found that the detection limit did not become altered [107], this set of primers having the highest detection limit (0.01 parasites/µL).

8. Lymphatic Filariasis

Lymphatic filariasis, commonly known as elephantiasis, is a disease caused by three parasite species: *Wuchereria bancrofti*, *Brugia malayi* and *Brugia timori* [119]; *W. bancrofti* is responsible for around 90% of reported cases [120]. The disease is caused by the bite of mosquitoes infected by filarial nematode larvae [121]. The disease is endemic in 73 countries and affects more than 120 million people around the world; Lourens and Ferrell have stated that around 1.1 billion people are at risk of becoming infected worldwide [121]. Infected people may be asymptomatic or even suffer serve incapacity; infection severity and intensity are determined by the duration of exposure to mosquito bites, the amount of accumulated adult larvae in the lymphatic vessels, a person’s particular immune response and the amount of secondary bacterial and fungal infections [122]. Acute infection is characterised by fever, chills, lymphadenopathy, myalgia and snoring due to microfilaria in the lungs; chronic infection is characterised by more localised symptoms such as pitting lymphedema and hydrocele, especially in the lower limbs [122].

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established in 2000 after WHO resolution WHA 50.29 had been adopted at its 1997 assembly (along with five other infectious diseases, as being eradicable or potentially eradicable). The objective was to eliminate the disease by 2020 by interrupting the disease’s transmission and dissemination by mass drug administration (MDA), managing morbidity and preventing disabilities [119–121,123,124].

Considering that only a third of infected patients develop symptoms [122], the availability of serological tests for detecting infection in humans and vector xenomonitoring enormously facilitates monitoring and evaluating programmes in endemic countries; however, using xenomonitoring in programmatic mode poses a challenge since (staff/operator) suitable experience and installations for performing the molecular assays must be available [124]. This becomes more difficult if one takes into account the WHO’s recommendation that evaluating molecular xenomonitoring and sampling mosquitoes should focus on individual villages (or a group of villages when target villages are small) [125]. The LAMP technique represents one way of achieving this. Studies have been carried out using different genes and ascertaining the test’s detection limit. The technique’s sensitivity has been tested using human blood and mosquito samples (Tables 10 and 11); the results have highlighted the technique’s potential usefulness for eradicating the disease.
Table 10. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing lymphatic filariasis in the definitive host.

| Parasite            | Gene                | Extracted/Spiked/ Natural DNA | Sample                  | Sample Size | Sensitivity Reference |
|---------------------|---------------------|------------------------------|-------------------------|-------------|-----------------------|
| B. malayi           | Hha I repeat (BmHha I) | Natural DNA                  | Human blood samples     | 8           | 1/100th of microfilaria (1 pg) [126] |
| W. bancrofti        | WbLDR               |                              |                         |             |                       |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Human blood samples     | Blood: 3067 | ND [127]              |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Human blood samples     | Blood: 3067 | ND [128]              |
| B. malayi or B. timori | Hha I repeat         | Extracted/ natural DNA       | Feline blood samples    | 1           | 0.001 ng [129]        |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Extracted/ spiked DNA        | Human blood             | -           | 1/100th of microfilaria [130] |

Table 11. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing lymphatic filariasis in the vector.

| Parasite            | Gene                | Extracted/Spiked/ Natural DNA | Sample                  | Sample Size | Sensitivity Reference |
|---------------------|---------------------|------------------------------|-------------------------|-------------|-----------------------|
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Mosquitoes              | 15,568      | ND [125]              |
| B. malayi           | Hha I repeat (BmHha I) | Natural DNA                  | Infected mosquitoes     | 8           | 1/100th of microfilaria (1 pg) [126] |
| W. bancrofti        | WbLDR               |                              |                         |             |                       |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Mosquitoes Mosquitoes:14,334 | ND          | [131]                |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Mosquitoes Mosquitoes:1,260 | ND          | [127]                |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Natural DNA                  | Mosquitoes Mosquitoes:16,073 | ND          | [128]                |
| W. bancrofti        | Nuclear scaffold/matrix attachment region | Extracted/ spiked DNA        | Mosquitoes             | -           | 1/100th of microfilaria [130] |

The nuclear scaffold/matrix attachment region sequence has been most used for W. bancrofti; however, Poole et al. [126] designed primers for the WbLDR sequence, improving the detection limit, passing from 1/1000th microfilaria [130] to 1/5000th microfilaria. The protocols were shown to have a detection limit equal to that of PCR [130] and qPCR [126]. Using the same protocol described by Takagi et al. [130], Kouassi et al. [131] found a larger amount of mosquitos positive by LAMP (1.8% of Anopheles gambiae and 0.31% of Culex spp.) than PCR (0% and 0.19%, respectively). The Hha I sequence has been used for standardising LAMP for diagnosing B. malayi, having a 1/100th microfilaria (1 pg) detection limit [126]. The protocol was used by Poole et al. [129] in a portable non-instrumented nucleic acid amplification (NINA) device, providing a stable heat source for LAMP, conserving its detection limit and having sensitivity equal to that of PCR.
9. Onchocerciasis (River Blindness)

Onchocerciasis, also known as river blindness, is a parasitic infection caused by *Onchocerca volvulus*. This filarial nematode is transmitted by black fly (*Simulium* spp.) bite [132]. The immunological reaction produced by the death of microfilaria is the mayor cause of morbidity; this is characterised by itching, skin depigmentation and lesions and visual disability which can progress to blindness [119]. It has been estimated that around 37 million people could be infected and 200 million at risk of contracting the infection [133]. The disease is endemic in sub-Saharan Africa, six Latin American countries and the Yemen [132].

Onchocerciasis eradication programmes have been focused on MDA for suppressing and eventually eliminating *O. volvulus* transmission. Children under ten years-old being exposed to the parasite is measured for demonstrating that transmission has been interrupted; current WHO guidelines state that the 95% confidence interval’s upper limit regarding this population’s prevalence of exposure cannot exceed 0.1% [134]. The follow-up test (Ov-16 ELISA) has 80% sensitivity and 97% specificity; a test having this level of specificity cannot measure 0.1%, meaning that tests having 99.9% specificity are required for achieving this [133]. LAMP techniques have thus been standardised, aimed at facilitating the detection of minimum amounts of antigen in both hosts and vectors (Tables 12 and 13), thereby making it a useful surveillance tool; however, there have been few developments in this area.

| Table 12. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing onchocerciasis (river blindness) in the definitive host. |
|-----------------------------|----------------|----------------|---------------|--------------|-----------------|-----------------|
| Parasite | Gene | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
| *O. volvulus* | Mitochondrial *cox1* | Extracted/natural DNA | Skin biopsies | 150 | ND | [135] |
| *O. volvulus* | O-150 | Extracted/natural DNA | Skin snips | 70 | 0.0001 ng | [136] |

| Table 13. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing onchocerciasis (river blindness) in the vector. |
|-----------------------------|----------------|---------------|--------------|-----------------|-----------------|
| Parasite | Gene | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
| *O. volvulus* | GST1a | Extracted DNA/Experimentally infected DNA | Black flies | 4 | 0.01 ng | [126] |
| *O. volvulus* | GST1a | Extracted/spiked DNA | Black flies | - | 0.01 ng | [137] |

The *O. volvulus* O-150 sequence has been studied for LAMP, having been shown to have a 0.0001 ng detection limit and to be 10-fold more sensitive than PCR. Higher sensitivity levels have been obtained using this protocol with clinical samples (skin biopsies), especially when using colorimetry (neutral red) instead of turbidimetry for taking the readings [136]. Poole et al. [129] used a NINA device when using the protocol described by Alhassan et al. [137], for identifying *O. volvulus* in black flies, having obtained the same detection limit as that for the original protocol and PCR.

10. Scabies

Scabies is a disease caused by the obligate parasite mite *Sarcoptes scabiei* var. *hominis*; this mite affects the skin’s stratum corneum where it induces a hypersensitivity reaction [138]. The 2016 Global Burden of Disease (GBD) study estimated that global point prevalence was around 147 million, accompanied by a 455 million case incidence annually [139]. The highest scabies rate is found in tropical regions, including East Asia, Southeast Asia, Southern Asia, Oceania and tropical Latin America [138]. This disease, one of the commonest worldwide, was incorporated into the list of NTDs by the WHO in 2017 [139].

Definitive diagnosis is mainly based on microscope observation of skin scrapings; however, scabies diagnosis cannot be ruled out just by a negative result as false negatives could occur when...
there are few mites [140]. ELISA tests and molecular techniques for amplifying nucleic acids (PCRs) have been developed as alternative methods [141]. Molecular methods also reduce the amount of false negatives and have enabled differentiating *S. scabiei* var. *hominis* infestation from a zoonotic infestation, e.g., *S. scabiei* var. *canis*, which cannot be differentiated via microscope and is important in terms of public health and for establishing treatment [141,142].

The difficulty involved in using PCR is that it requires specialised infrastructure and equipment. So, once again, the LAMP technique becomes a good diagnosis option for communities living in remote places and having limited access to laboratories. Unfortunately, very few approaches have been made in this field (Table 14).

### Table 14. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing scabies in the definitive host.

| Parasite Gene Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
|------------------------------------------|--------|-------------|-------------|-----------|
| *S. scabiei* ITS-2 Extracted/natural DNA  | Mite/animal skin scrapings | 64 | Single mite DNA: 0.02 ng Skin scraping: 0.008 ng | [141] |

In spite of the published protocol’s detection limit being stated in nanograms (i.e., when most protocols use femtograms or picograms), Fraser et al. [141] obtained 100% sensitivity (0.86–1.00 95% CI) and 92.50% specificity (0.80–0.98 95% CI) when comparing LAMP results with those for PCR.

### 11. Schistosomiasis

Schistosomiasis, also known as bilharzia, is a tropical parasitic disease causing significant morbidity and mortality rates, especially in developing countries; it is the third most reported tropical disease and the second most reported in the sub-Saharan region [143]. Several *Schistosoma* species have been described; however, most cases are attributed to three species in particular: *Schistosoma haematobium*, *Schistosoma japonicum* and *Schistosoma mansoni*. Reports of the disease being caused by species such as *Schistosoma mekongi* and *Schistosoma intercalatum* are less common [143]. *S. haematobium* and *S. mansoni* are the most prevalent species in Africa and the Middle East whereas only *S. mansoni* occurs in Latin America and *S. japonicum* in Asia [144].

It has been estimated that around 250 million people are affected by the disease worldwide and more than 779 million are at risk of becoming infected, causing close to 280,000 deaths annually [145]. This makes it one of the five zoonotic diseases whose global health rate has been underestimated [143]. These blood-feeding flukes are responsible for significant clinical complications involving the liver, intestines, spleen and bladder, leading to chronic inflammation and fibrosis [146].

Programmes must involve intensive intervention measures and efficient monitoring to ensure success regarding the disease’s prevention and elimination [146]. The difficulty in demonstrating significant reductions in infection levels in regions having very low prevalence and basal intensity is one of the challenges involved in eliminating the parasite [147]. The techniques usually used for diagnosing the disease include conventional microscope diagnosis, serological tests determining the presence of antibodies, tests for detecting parasite antigens and DNA detection methods (PCR) [146].

Molecular techniques used for DNA detection have aroused much interest considering that an ideal schistosomiasis diagnosis must be highly sensitive and specific, be easy to use and interpret, rapid, low cost, capable of using/processing different types of sample and be potentially applicable in disease-endemic areas having extremely limited economic resources. LAMP is a technique which meets all such requirements and therefore represents an alternative tool regarding other more complex molecular methods [148]. Several approaches have thus been made for standardising and using it (Tables 15 and 16), although such tests are still not widely available.
### Table 15. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing schistosomiasis in the definitive host.

| Parasite       | Gene                     | Extracted/Spiked/ Natural DNA Sample | Sample Size | Sensitivity | Reference |
|----------------|--------------------------|-------------------------------------|-------------|-------------|-----------|
| *S. mansoni*   | ITS-1                    | Extracted DNA Adult worms            | -           |             | [149]     |
| *S. intercalatum* | Mitochondrial minisatellite DNA region | Spiked/ natural DNA Cutaneous and hepatic biopsies and appendix biopsy | 3           | ND          | [150]     |
| *S. mansoni*   | Sm1-7 repeat fragment    | Natural DNA Human urine and stool    | 111         | ND          | [151]     |
| *S. haematobium* | IGS                      | Natural DNA Human urine             | 172         | ND          | [152]     |
| *S. mansoni*   | Sm1-7 repeat fragment    | Extracted/ natural DNA Human faeces | 383         | 32 fg       | [153]     |
| *S. mansoni*   | Mitochondrial minisatellite DNA region | Natural DNA Human faeces            | 427         | ND          | [154]     |
| *S. haematobium* | Dral repeat fragment     | Natural DNA Egyptian strain, NR-31682/human urine samples | 94          | 1 fg        | [155]     |
| *S. japonicum* | 28S-18S ribosomal RNA    | Natural DNA Human serum             | 110         | ND          | [156]     |
| *S. mansoni*   | Sm1-7 repeat fragment    | Experimentally infected DNA Mice faeces | -           | 1 fg        | [157]     |
| *S. japonicum* | Highly repetitive retrotransposon (SpJ2) | Natural DNA Rabbit faeces         | 6           | 0.08 fg     | [158]     |

S. mansoni has been the most studied *Schistosoma* species, the mitochondrial minisatellite DNA region and Sm1-7 repeat fragment sequences more than others. The mitochondrial minisatellite DNA region sequence has been shown to have the best detection limit (0.01 fg [152]) when using the primers designed by Fernández-Soto et al. [158]. The authors modified the protocol for obtaining this limit, increasing incubation time from 60 to 120 minutes; this improved analytical sensitivity from 1 fg to 0.01 fg and increasing incubation time did not affect test specificity. Using this set of primers which had already been tested in urine [152], faeces [158] and snails [155], the research group improved the protocol, transforming it into a cold maintenance dry format, suitable for potentially manufacturing as a kit for ready-to-use for schistosomiasis diagnosis [150]. Price et al. [151] amplified the Sm1-7 sequence for evaluating the effect of extraction on LAMP performance, finding greater sensitivity.

### Table 16. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing schistosomiasis in the vector.

| Parasite       | Gene                     | Extracted/Spiked/ Natural DNA Sample | Sample Size | Sensitivity | Reference |
|----------------|--------------------------|-------------------------------------|-------------|-------------|-----------|
| *S. mansoni*   | 28S ribosomal (S28S) gene | Natural DNA Snail soft tissues      | 4006 a      | 1/50        | [159]     |
| *S. mansoni*   | Mitochondrial minisatellite DNA region | Natural DNA Snail soft tissues | 1175 b     | ND          | [155]     |
| *S. mansoni*   | ITS                      | Natural DNA Snail soft tissues      | Individually: 11 Pools: 8 | 70 fg      | [160]     |
| *S. mansoni*   | IGS                      | Natural DNA Snail soft tissues      | 41          | 1 fg        | [161]     |
| *S. haematobium* | Dral repeat fragment     | Natural DNA Snail soft tissues      | 103         | 0.1 fg      | [162]     |
| *S. mansoni*   | Sm1-7 repeat fragment    | Natural DNA Snail soft tissues      | 11          | 0.1 fg      | [163]     |
| *S. japonicum* | 28S rDNA gene            | Natural DNA Snail soft tissues      | 362         | 100 fg      | [164]     |

S. mansoni has been the most studied *Schistosoma* species, the mitochondrial minisatellite DNA region and Sm1-7 repeat fragment sequences more than others. The mitochondrial minisatellite DNA region sequence has been shown to have the best detection limit (0.01 fg [152]) when using the primers designed by Fernández-Soto et al. [158]. The authors modified the protocol for obtaining this limit, increasing incubation time from 60 to 120 minutes; this improved analytical sensitivity from 1 fg to 0.01 fg and increasing incubation time did not affect test specificity. Using this set of primers which had already been tested in urine [152], faeces [158] and snails [155], the research group improved the protocol, transforming it into a cold maintenance dry format, suitable for potentially manufacturing as a kit for ready-to-use for schistosomiasis diagnosis [150]. Price et al. [151] amplified the Sm1-7 sequence for evaluating the effect of extraction on LAMP performance, finding greater sensitivity.
and specificity when samples were extracted with a LAMP-Qiagen kit (100% sensitivity: 96–100% 95% CI; 100% specificity: 59–100% 95% CI), compared to using PCR-Qiagen, PCR_LAMP-PURE, LAMP_LAMP_PURE kits.

The ITS-1 [149], IGS [153,156] and DraI [163,164] sequences have been studied for S. haematobium diagnosis, a greater detection limit having been obtained with DraI (0.1 fg). Gandasegui et al. [153] worked with the IGS region, finding a larger amount of samples to be positive by colorimetry than by turbidimetry (i.e., when adding SYBR Green I to the reaction); however, the effect of the extraction method has been controversial since Gandasegui et al. [153] found that sensitivity was greater when DNA was extracted with a commercial kit. Gandasegui et al. [156] found greater sensitivity when working with the Rapid-Heat LAMPellet method when the test was done from urine sample supernatant or sediment, finding more positive individuals when working with DNA from sediment.

Even though the best detection limit was not obtained for S. mansoni (1 pg) or S. haematobium (0.1 pg) with the ITS-1 region, the primers designed for amplifying this region can be used for detecting different Schistosoma species (S. haematobium, S. intercalatum, S. mansoni and S. bovis).

12. Soil-Transmitted Helminthiases (Intestinal Worms)

It has been estimated that around 2 billion people (almost a quarter of the world’s population) are infected by STHs [166], causing around 135,000 deaths per year [167]. Most of these infections are caused by roundworms (Ascaris lumbricoides and Strongyloides stercoralis), whipworms (Trichuris trichiura) and hookworms (Necator americanus or Ancylostoma duodenale) [168]. The WHO has included Ascaris lumbricoides, Trichuris trichiura, Necator americanus and Ancylostoma duodenale in its list of STH-caused NTDs [169]. Although each species has specific characteristics, the WHO groups STHs for control purposes in terms of similarity between geographically-defined endemic groups and the risk of becoming affected, treatment involving the same drugs, using the same tools for diagnosis and involving a similar mechanism having negative impact on human health [166]. These parasites are endemic in more than 100 countries [166], being more prevalent in developing regions in Africa, Asia and the Americas as well as being the most prevalent NTDs worldwide [169].

The WHO has endorsed a preventative chemotherapy strategy for controlling STH-related morbidity without needing prior individual diagnosis for groups at specific risk who are living in endemic areas, this being the most profitable approach [166]. Ab-based assays for STH diagnosis and widely-used faeces’ microscopy (although these are not standardised) may help primo-infection diagnosis and cases where microscopy has proved negative [170].

Work is currently underway regarding the development of a PCR for clinical management and public health, although the tests are still not widely available [170]. Developing techniques having high specificity will contribute towards knowledge regarding real prevalence in target regions due to the costs incurred in adapting/updating infrastructure and providing the necessary equipment for carrying out immunoassays or PCRs. It must be borne in mind that eliminating eggs from faeces is intermittent when attempting to establish the control programmes proposed in the WHO’s Guidelines: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups [166].

This makes the LAMP technique a good option regarding less specialised infrastructure and equipment requirements, being cheaper and a test having greater specificity [169]; however, few approaches to date have involved using this technique (Table 17). This technique’s validation and use will enable filling one of the gaps found in the WHO’s 2017 guidelines concerning its recommendations about the need for new field diagnosis for detecting and treating target groups and monitoring the impact of preventative chemotherapy on morbidity and transmission [171].
Table 17. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing soil-transmitted helminthiases (intestinal worms) in the definitive host.

| Parasite       | Gene             | Extracted/Spiked/Natural DNA | Sample               | Sample Size | Sensitivity                  | Reference |
|----------------|------------------|------------------------------|----------------------|-------------|-----------------------------|-----------|
| *T. trichiura* | ITS-2            | Natural DNA                  | Human faeces         | 137         | $98.6 \times 10^{-9}$ ng/µL or a single egg | [172]     |
| *Strongyloides* spp. | 18S rRNA        | Natural DNA                  | Human urine          | 24          | ND                          | [173]     |
| *A. lumbricoides* | β-tubulin isotype 1 | Extracted/natural/spiked DNA | Human faeces         | 21          | 1 pg or a single egg         | [174]     |
| *N. americanus* | ITS-1            | Natural DNA                  | Human faeces         | 581         | $10.8$ ng (equivalent to a single egg) | [175]     |
| *N. americanus* | ITS-2            | Natural DNA                  | Human faeces         | 106         | 0.4 fg                       | [176]     |

Different genes have been studied for diagnosing intestinal worms, all being able to detect at least 1 egg. Regarding *Strongyloides* spp., LAMP sensitivity ($10^{-3}$ ng) was greater than PCR sensitivity (0.1 ng) when amplifying the 18S rRNA sequence from DNA extracted from *S. venezuelensis* [175]. No positive PCR results were obtained when using the same primers on urine samples [173]. Concerning *T. trichiura*, the set of primers which amplified the ITS-2 region designed by Ngari et al. [172] was able to detect very low levels of infection, having greater sensitivity than the Kato–Katz technique. Even though the detection limit obtained by Rashwan et al. [174] after designing primers amplifying the β-tubulin region was not better (1 pg), the advantage of this protocol lies in its ability to detect *T. trichiura*, *A. lumbricoides* and *N. americanus* eggs. Even though the Kato–Katz technique’s sensitivity and specificity are low and LAMP’s detection limit is considered good, work is still needed on optimising protocols for improving the sensitivity and specificity obtained for *T. trichiura* (77% sensitivity, 88% specificity [172]) and for *A. lumbricoides* (96.3% sensitivity, 61.5% specificity [176]).

13. Taeniasis/Cysticercosis

Human taeniasis is a worldwide parasitic infection, although communities in developing countries bear the greatest burden. Three species can affect humans: *Taenia saginata* (the beef tapeworm), *Taenia solium* (the pork tapeworm) and *Taenia asiatica* (the Asian tapeworm) [178]. Neurocysticercosis (NCC) causes 29% of neurological crises [179]; it is caused by the pork tapeworm’s larval stage and should not be confused with the type of taeniasis resulting from adult tapeworm infection [180]. *T. solium* occupied first place in the global scale of food-transmitted parasites in 2014 [181]. Latin America, Africa, South East Asia, India, China and Nepal are endemic areas for NCC [180]. The WHO included NCC caused by *T. solium* in its 2012 route map for addressing NTDs, highlighting it as a neglected zoonotic disease (NZD) [181].

MDA involves treating most non-infected people, which, in this case, involves incurring high costs and treatment-associated risks, selective treatment can thus be considered an alternative. However, it involves difficulties due to diagnosis limitations related to identifying carriers since the symptoms are vague and there is a lack of availability of sensitive, specific and applicable detection methods in endemic areas as well as the costs involved in such procedure [181].

The LAMP technique would be a very useful tool for contributing towards reducing the cysticercosis rate in developing regions, except when cysticerci are calcified since there are no circulating antigens during this stage. The WHO’s Department of Control of Neglected Tropical Diseases (WHO/NTD) and the Special Programme for Research and Training in Tropical Diseases met in 2015 to discuss the difficulties regarding *T. solium* diagnosis; consensus was reached indicating that
diagnosis should include the different Taenia species to facilitate the diagnosis and control of other infections caused by Taenia spp.

Likewise, there was consensus that diagnosis should focus on symptomatic patients for detecting people having viable cysts and who needed to be referred for diagnostic imaging and other procedures/management, including anti-helminth treatment. This took into account rural and remote communities where the disease is endemic and having suitable diagnostic facilities/installations [179]. The LAMP technique requires further work with symptomatic patients to demonstrate its usefulness in diagnosing them, even though its good detection limit has been highlighted and it can be carried out in the field using little specialised equipment (Table 18).

Table 18. Publications found in the US National Library of Medicine National Institutes of Health (NCBI-PubMed) reporting the standardisation of the LAMP technique as a useful tool for diagnosing taeniasis/cysticercosis in the definitive host.

| Parasite | Gene | Extracted/Spiked/Natural DNA | Sample | Sample Size | Sensitivity | Reference |
|----------|------|-----------------------------|--------|-------------|-------------|-----------|
| T. solium | cox1 | Extracted/natural DNA       | Human faeces | 102          | 1 copy of target gene | [182] |
| T. solium | cox1 | Natural DNA                 | Tapeworms | 51           | ND          | [183] |
| T. solium | cox1 and clp | Natural DNA | Human faeces | 36           | ND          | [184] |
| T. solium | cox1 and clp | Extracted DNA | Proglottids and cysticerci | 168         | 1 copy of target gene | [185] |

All the articles published that were related to standardising a LAMP for diagnosing T. solium came from the same group, which itself worked mostly with the cox1 sequence due its ability for differentiating between the three Taenia species (T. solium, T. saginata and T. asiatica), plus greater capacity for detecting positive samples. The protocols used have been shown to be able to detect the parasite’s different stages and have greater sensitivity than multiplex PCR.

14. Conclusions

The authors referenced here have demonstrated greater sensitivity for the LAMP technique than PCR in almost all cases whether the DNA used in a test came from natural infections or reference strains, regardless of parasite genus or species; in the few cases in which the test did not surpass PCR detection limit, it at least equalled it. This led to all authors coinciding in concluding that LAMP is a simpler and cheaper technique since it requires less sophisticated equipment, thereby enabling the test to be carried out in conventional laboratories or even directly in the field. This makes the technique a useful tool for contributing toward surveillance and control programmes aimed at eliminating NPI.

Author Contributions: Conceptualization, C.A. and M.A.P.; writing—original draft preparation, C.A; writing—review and editing, M.A.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We would like to thank the Universidad del Rosario for assuming open access charges. We would like to thank Jason Garry for translating this manuscript.

Conflicts of Interest: The authors declare that there are no conflicts of interest regarding the publication of this paper.

Abbreviations

BIP  backward inner primer
CL  cutaneous leishmaniasis
clp  cathepsin L-like cysteine peptidase
cox1  cytochrome c oxidase subunit 1
CPB  cysteine protease B
CSF  cerebrospinal fluid
DNA  deoxyribonucleic acid
DTUs  discrete typing units
FIP forward inner primer
FTA Flinders Technology Associates
GBD global burden of disease
GPELF global programme to eliminate lymphatic filariasis
GST1a glutathione-1 transferase-1
HAT human African trypanosomiasis
IGS ribosomal intergenic spacer
IACR International Agency of Cancer Research
ITS internal transcribed spacer
ITS-1 internal transcribed spacer 1 region
ITS-2 the second internal transcribed spacer region
fg femtogram
kDNA kinetoplast DNA minicircle sequence
LAMP loop-mediated isothermal amplification
LB loop backward
LDR long DNA repeat
LF loop forward
MDA mass drug administration
MCL mucocutaneous leishmaniasis
nad1 NADH dehydrogenase subunit 1
nad5 NADH dehydrogenase subunit 5
NADH nicotinamide adenine dinucleotide (NAD) + hydrogen
ND not determined
NINA non-instrumented nucleic acid amplification
NPI neglected parasite infections
NTD neglected tropical disease
NZD neglected zoonotic disease
ng nanogram
PCR polymerase chain reaction
PFR paraflagellar rod
pg picogram
RBC red blood cell
RIME repetitive insertion mobile element
rDNA ribosomal deoxyribonucleic acid
rRNA ribosomal ribonucleic acid
SDS Sodium dodecyl sulfate
STH soil-transmitted helminths
SRA human serum resistance-associated
SGP specific glycoprotein
VL visceral leishmaniasis
WHA World Health Assembly
WHO World Health Organisation

References
1. Chami, G.F.; Bundy, D.A.P. More medicines alone cannot ensure the treatment of neglected tropical diseases. *Lancet Infect. Dis.* 2019, 19, e330–e336. [CrossRef]
2. Akinsolu, F.T.; Nemieboka, P.O.; Njuguna, D.W.; Ahadjji, M.N.; Dezso, D.; Varga, O. Emerging resistance of neglected tropical diseases: A scoping review of the literature. *Int. J. Environ. Res. Public Health* 2019, 16, 1925. [CrossRef] [PubMed]
3. Mitra, A.; Mawson, A. Neglected Tropical Diseases: Epidemiology and Global Burden. *Trop. Med. Infect. Dis.* 2017, 2, 36. [CrossRef]
4. Booth, M.; Clements, A. Neglected tropical disease control – The case for adaptive, location-specific solutions. *Trends Parasitol.* 2018, 34, 272–282. [CrossRef] [PubMed]
5. Peeling, R.W.; Boeras, D.I.; Nkengasong, J. Re-imagining the future of diagnosis of Neglected Tropical Diseases. Comun. Struct. Biotechnol. J. 2017, 15, 271–274. [CrossRef] [PubMed]

6. Notomi, T.; Okayama, H.; Masubuchi, H.; Yonekawa, T.; Watanabe, K.; Amino, N.; Hase, T. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000, 28, e63. [CrossRef] [PubMed]

7. Notomi, T.; Mori, Y.; Tomita, N.; Kanda, H. Loop-mediated isothermal amplification (LAMP): Principle, features, and future prospects. J. Microbiol. 2015, 53, 1–5. [CrossRef] [PubMed]

8. Shirato, K. Detecting amplicons of loop-mediated isothermal amplification. Microbiol. Immunol. 2019, 63, 407–412. [CrossRef]

9. Wong, Y.P.; Othman, S.; Lau, Y.L.; Radu, S.; Chee, H.Y. Loop-mediated isothermal amplification (LAMP): A versatile technique for detection of micro-organisms. J. Appl. Microbiol. 2018, 124, 626–643. [CrossRef]

10. Wastling, S.L.; Picozzi, K.; Kakembo, A.S.L.; Welburn, S.C. LAMP for human African trypanosomiasis: A comparative study of detection formats. PLoS Negl. Trop. Dis. 2010, 4, e865. [CrossRef]

11. Nikolskaia, O.V.; Thekisoe, O.M.; Stephen Dumler, J.; Grab, D.J. Loop-Mediated isothermal amplification for detection of the 5.8s ribosomal ribonucleic acid internal transcribed spacer 2 gene found in Trypanosoma brucei gambiense. Am. J. Trop. Med. Hyg. 2017, 96, 275–279. [CrossRef] [PubMed]

12. Van Nguyen, D.; Nguyen, V.H.; Seo, T.S. Quantification of Colorimetric Loop-mediated Isothermal Amplification Process. Biochips. J. 2019, 13, 158–164. [CrossRef]

13. Wang, X.; Fu, Z.; Chen, X.; Peng, C.; Xu, X.; Wei, W.; Li, F.; Xu, J. Use of a novel metal indicator to judge loop-mediated isothermal amplification for detecting the 35S promoter. Anal. Bioanal. Chem. 2017, 409, 881–889. [CrossRef] [PubMed]

14. Tanner, N.A.; Zhang, Y.; Evans, T.C. Visual detection of isothermal nucleic acid amplification using pH-sensitive dyes. Biotechniques 2015, 58, 59–68. [CrossRef]

15. Nzelu, C.O.; Gomez, E.A.; Cáceres, A.G.; Sakurai, T.; Martini-Robles, L.; Uezato, H.; Mimori, T.; Katakura, K.; Hashiguchi, Y.; Kato, H. Development of a loop-mediated isothermal amplification method for rapid mass-screening of sand flies for Leishmania infection. Acta Trop. 2014, 132, 1–6. [CrossRef]

16. Tong, Q.; Chen, R.; Kong, Q.; Goossens, J.; Radwanska, M.; Lou, D.; Ding, J.; Zheng, B.; Fu, Y.; Wang, T.; et al. DNA detection of Trypanosoma cruzi: Diagnostic validity of a new assay based on loop-mediated isothermal amplification (LAMP). Vet. Parasitol. 2018, 250, 1–6. [CrossRef]

17. Kiatpathomchai, W.; Jaroenram, W.; Arunrut, N.; Jitrapakdee, S.; Flegel, T.W. Shrimp Taura syndrome virus detection by reverse transcription loop-mediated isothermal amplification combined with a lateral flow dipstick. J. Virol. Methods 2008, 153, 214–217. [CrossRef]

18. Li, S.; Liu, Y.; Wang, Y.; Chen, H.; Liu, C.; Wang, Y. Lateral flow biosensor combined with loop-mediated isothermal amplification for simple, rapid, sensitive, and reliable detection of Brucella spp. Infect. Drug Resist. 2019, 12, 2343–2353. [CrossRef]

19. Priye, A.; Bird, S.W.; Light, Y.K.; Ball, C.S.; Negrete, O.A.; Meagher, R.J. A smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses. Sci. Rep. 2017, 7, 44778. [CrossRef]

20. Kong, J.E.; Wei, Q.; Tseng, D.; Zhang, J.; Pan, E.; Lewinski, M.; Garner, O.B.; Ozcan, A.; Di Carlo, D. Highly stable and sensitive nucleic acid amplification and cell-phone-based readout. ACS Nano 2017, 11, 2934–2943. [CrossRef]

21. Sun, F.; Ganguli, A.; Nguyen, J.; Brisbin, R.; Shanmugam, K.; Hirschberg, D.L.; Wheeler, M.B.; Bashir, R.; Nash, D.M.; Cunningham, B.T. Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract. Lab Chip 2020, 20, 1621–1627. [CrossRef] [PubMed]

22. Nzelu, C.O.; Kato, H.; Peters, N.C. Loop-mediated isothermal amplification (LAMP): An advanced molecular point-of-care technique for the detection of Leishmania infection. PLoS Negl. Trop. Dis. 2019, 13, e0007698. [CrossRef] [PubMed]

23. Thekisoe, O.M.M.; Bazie, R.S.B.; Coronel-Servian, A.M.; Sugimoto, C.; Kawazu, S.; Inoue, N. Stability of loop-mediated isothermal amplification (LAMP) reagents and its amplification efficiency on crude trypanosome DNA templates. J. Vet. Med. Sci. 2009, 71, 471–475. [CrossRef] [PubMed]

24. Njiru, Z.K.; Mikosza, A.S.J.; Matovu, E.; Enyaru, J.C.K.; Ouma, J.O.; Kibona, S.N.; Thompson, R.C.A.; Ndung’u, J.M. African trypanosomiasis: Sensitive and rapid detection of the sub-genus Trypanozoon by loop-mediated isothermal amplification (LAMP) of parasite DNA. Int. J. Parasitol. 2008, 38, 589–599. [CrossRef]
25. Matovu, E.; Katiti, D.; Kitibwa, A.; Kazibwe, A.J.; Kato, C.D.; Bieler, S.; Ndung’u, J.M. Optimisation of template preparation and laboratory evaluation of the Loopamp™ Trypanosoma brucei kit for detection of parasite DNA in blood. *Exp. Parasitol.* 2020, 211, 107844. [CrossRef]

26. Grab, D.J.; Nikolskaia, O.V.; Inoue, N.; Thekisoe, O.M.M.; Morrison, L.J.; Gibson, W.; Dumler, J.S. Using detergent to enhance detection sensitivity of African trypanosomes in human CSF and blood by loop-mediated isothermal amplification (LAMP). *PLoS Negl. Trop. Dis.* 2011, 5, e1249. [CrossRef]

27. Grab, D.J.; Nikolskaia, O.V.; Courtioux, B.; Thekisoe, O.M.M.; Magez, S.; Bogorad, M.; Dumler, J.S.; Bisser, S. Using detergent-enhanced LAMP for African trypanosome detection in human cerebrospinal fluid and implications for disease staging. *PLoS Negl. Trop. Dis.* 2019, 13, e0007631. [CrossRef]

28. Sulleiro, E.; Muñoz-Calderon, A.; Schijman, A.G. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials. *Acta Trop.* 2019, 199, 105120. [CrossRef]

29. Guarner, J. Chagas disease as example of a reemerging parasite. *Semin. Diagn. Pathol.* 2019, 36, 164–169. [CrossRef]

30. Pérez-Molina, J.A.; Molina, I. Chagas disease. *Lancet* 2018, 391, 82–94. [CrossRef]

31. Besuschio, S.A.; Llano Murcia, M.; Benatar, A.F.; Monnerat, S.; Cruz Mata, I.; Picado de Puig, A.; de los Ángeles Curto, M.; Kubota, Y.; Wehrndt, D.P.; Pavia, P.; et al. Analytical sensitivity and specificity of a loop-mediated isothermal amplification (LAMP) kit prototype for detection of Trypanosoma cruzi DNA in human blood samples. *PLoS Negl. Trop. Dis.* 2017, 11, e005779. [CrossRef]

32. Alonso-Padilla, J.; Cortés-Serra, N.; Pinazo, M.; Bottazzi, M.E.; Abril, M.; Barreira, F.; Sosa-Estani, S.; Hotez, P.J.; Gascón, J. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. *Expert Rev. Anti-Infect. Ther.* 2019, 17, 145–157. [CrossRef]

33. Ordóñez, D.; Fernández-Soto, P.; Fernández-Martin, A.M.; Crego-Vicente, B.; Febrer-Sendra, B.; García Bernalt Diego, J.; Vicente, B.; López-Abán, J.; Belhassen-Garcia, M.; Muro, A.; et al. A *Trypanosoma cruzi* genome tandem repetitive satellite DNA sequence as a molecular marker for a LAMP assay for diagnosing chagas’ disease. *Dis. Markers* 2020, 2020. [CrossRef]

34. Rivera, R.; Bisio, M.; Velázquez, E.B.; Esteva, M.I.; Scollo, K.; González, N.L.; Alcheh, J.; Ruiz, A.M. Rapid detection of *Trypanosoma cruzi* by colorimetric loop-mediated isothermal amplification (LAMP): A potential novel tool for the detection of congenital Chagas infection. *Diagn. Microbiol. Infect. Dis.* 2017, 89, 26–28. [CrossRef] [PubMed]

35. Thekisoe, O.M.M.; Coronel-Servian, A.M.; Fukumoto, S.; Kawazu, S.I.; Inoue, N.; Rodriguez, C.V.; Rivas, F.; Sugimoto, C. Detection of *Trypanosoma cruzi* and *T. rangeli* infections from *Rhodnius pallescens* bugs by loop-mediated isothermal amplification (LAMP). *Am. J. Trop. Med. Hyg.* 2010, 82, 855–860. [CrossRef] [PubMed]

36. Thekisoe, O.M.M.; Kuboki, N.; Nambota, A.; Fujisaki, K.; Sugimoto, C.; Igarashi, I.; Yasuda, J.; Inoue, N. Species-specific loop-mediated isothermal amplification (LAMP) for diagnosis of trypanosomosis. *Acta Trop.* 2007, 102, 182–189. [CrossRef]

37. Wen, H.; Vuitton, L.; Tuxun, T.; Li, J.; Vuitton, D.A.; Zhang, W.; Mcmanus, P. Echinococcosis: Advances in the 21st Century. *Clin. Microbiol. Rev.* 2019, 32, e00075-18. [CrossRef]

38. Bhutani, N.; Kajal, P. Hepatic echinococcosis: A review. *Ann. Med. Surg.* 2018, 36, 99–105. [CrossRef] [PubMed]

39. Larrieu, E.; Gavidia, C.M.; Lightowlers, M.W. Control of cystic echinococcosis: Background and prospects. *Zoonoses Public Health* 2019, 66, 889–899. [CrossRef]

40. Fadel, S.A.; Asmar, K.; Faraj, W.; Khalife, M.; Haddad, M.; El-Merhi, F. Clinical review of liver hydatid disease and its unusual presentations in developing countries. *Abdom. Radiol.* 2019, 44, 1331–1339. [CrossRef]

41. Ahmed, M.E.; Eldigail, M.H.; Elamin, F.M.; Ali, I.A.; Grobusch, M.P.; Aradaib, I.E. Development and evaluation of real-time loop-mediated isothermal amplification assay for rapid detection of cystic echinococcosis. *BMC Vet. Res.* 2016, 12, 202. [CrossRef] [PubMed]

42. Avila, H.G.; Mozzoni, C.; Trangoni, M.D.; Cravero, S.L.P.; Pérez, V.M.; Valenzuela, F.; Gertiser, M.L.; Butti, M.J.; Kamenetzky, L.; Jensen, O.; et al. Development of a copro-LAMP assay for detection of several species of *Echinococcus granulosus* sensu lato complex. *Vet. Parasitol.* 2020, 277, 109017. [CrossRef] [PubMed]

43. Wassermann, M.; Mackenstedt, U.; Romig, T. A loop-mediated isothermal amplification (LAMP) method for the identification of species within the *Echinococcus granulosus* complex. *Vet. Parasitol.* 2014, 200, 97–103. [CrossRef] [PubMed]
44. Xingwei, N.; McManus, D.P.; Hongbin, Y.; Jifei, Y.; Zhongzi, L.; Hongmin, L.; Li, L.; Mengtong, L.; Jinzhong, C.; Yanlei, F.; et al. Loop-Mediated Isothermal Amplification (LAMP) assay for the identification of *Echinococcus multilocularis* infections in canine definitive hosts. Parasites Vectors 2014, 7, 1–8.

45. Ni, X.-W.; McManus, D.P.; Lou, Z.Z.; Yang, J.F.; Yan, H.B.; Li, L.; Li, H.M.; Liu, Q.Y.; Li, C.H.; Shi, W.G.; et al. A comparison of loop-mediated isothermal amplification (LAMP) with other surveillance tools for *Echinococcus granulosus* diagnosis in canine definitive hosts. *PLoS ONE* 2014, 9, 5–11. [CrossRef]

46. Salant, H.; Abbasi, I.; Hamburger, J. The development of a loop-mediated isothermal amplification method (LAMP) for *Echinococcus granulosus* coprodiagnosis. *Am. J. Trop. Med. Hyg.* 2012, 87, 883–887. [CrossRef]

47. Kruithof, R.; Erard, V. Trématodoses alimentaires. *Rev. Med. Suisse* 2017, 13, 1741–1744.

48. Pérez-Ponce de León, G.; Nadler, S.A. The importance of recognising parasite cryptic diversity for research programmes on foodborne trematodiases. *Trans. R. Soc. Trop. Med. Hyg.* 2015, 110, 4–5. [CrossRef]

49. Toledo, R.; Esteban, J.G.; Fried, B. Current status of food-borne trematode infections. *Eur. J. Clin. Microbiol. Infect. Dis.* 2012, 31, 1705–1718. [CrossRef]

50. Tang, Z.L.; Huang, Y.; Yu, X.B. Current status and perspectives of *Clonorchis sinensis* and clonorchiasis: Epidemiology, pathogenesis, omics, prevention and control. *Infect. Dis. Poverty* 2016, 5, 1–12. [CrossRef]

51. Lai, D.H.; Hong, X.K.; Su, B.X.; Liang, C.; Hide, G.; Zhang, X.; Yu, X.; Lun, Z.R. Current status of *Clonorchis sinensis* and clonorchiasis in China. *Trans. R. Soc. Trop. Med. Hyg.* 2015, 110, 21–27. [CrossRef]

52. Deng, Z.H.; Fang, Y.Y.; Zhang, Q.M.; Mao, Q.; Pei, F.Q.; Liu, M.R. The control of clonorchiasis in Guangdong province, southern China. *Acta Trop.* 2020, 202, 105246. [CrossRef]

53. Suwannatrai, A.; Saichua, P.; Haswell, M. Epidemiology of *Opisthorchis viverrini* infection. In *Advances in Parasitology*, Sripa, B., Brindley, P.J., Eds.; Academic Press: Cambridge, MA, USA, 2018; Volume 101, pp. 41–67, ISBN 9780128145760.

54. Prasopdee, S.; Thitapakorn, V.; Sathavornmanee, T.; Tesana, S. A comprehensive review of omics and host-parasite interplays studies, towards control of *Opisthorchis viverrini* infection for prevention of cholangiocarcinoma. *Acta Trop.* 2019, 196, 76–82. [CrossRef] [PubMed]

55. Wébb, C.M.; Cabada, M.M. Recent developments in the epidemiology, diagnosis, and treatment of Fasciola infection. *Curr. Opin. Infect. Dis.* 2018, 31, 409–414. [CrossRef]

56. Rojas-Caraballo, J.; López-Abán, J.; Moreno-Pérez, D.A.; Vicente, B.; Fernández-Soto, P.; del Olmo, E.; Patarroyo, M.A.; Muro, A. Transcriptome profiling of gene expression during immunisation trial against *Fasciola hepatica*: Identification of genes and pathways involved in conferring immunoprotection in a murine model. *BMC Infect. Dis.* 2017, 17, 94. [CrossRef]

57. Mehmood, K.; Zhang, H.; Sabir, A.J.; Abbas, R.Z.; Ijaz, M.; Durrani, A.Z.; Saleem, M.H.; Ur Rehman, M.; Iqbal, M.K.; Wang, Y.; et al. A review on epidemiology, global prevalence and economical losses of fasciolosis in ruminants. *Microb. Pathog.* 2019, 109, 253–262. [CrossRef] [PubMed]

58. Yoshida, A.; Doanh, P.N.; Maruyama, H. *Paragonimus* and paragonimiasis in Asia: An update. *Acta Trop.* 2019, 199, 105074. [CrossRef]

59. Cumberledge, N.; Rollinson, D.; Vercruysse, J.; Tchuen Tchuenté, L.A.; Webster, B.; Clark, P.F. *Paragonimus* and paragonimiasis in West and Central Africa: Unresolved questions. *Parasitology* 2018, 145, 1748–1757. [CrossRef] [PubMed]

60. Fischer, P.U.; Weil, G.J. North American paragonimiasis: Epidemiology and diagnostic strategies. *Expert Rev. Anti. Infect. Thor.* 2015, 13, 779–786. [CrossRef]

61. Rahmen, S.; Song, H.; Jin, Y.; Oh, J.-K.; Lim, M.; Hong, S.-T.; Choi, M.-H. Application of a loop-mediated isothermal amplification (LAMP) assay targeting *cox1* gene for the detection of *Clonorchis sinensis* in human fecal samples. *PLoS Negl. Trop. Dis.* 2017, 11, e0005995. [CrossRef] [PubMed]

62. Ghodsian, S.; Rouhani, S.; Fallahi, S.; Seyyed-Tabaei, S.J.; Taghipour, N. Detection of spiked *Fasciola hepatica* eggs in stool specimens using LAMP technique. *Iran. J. Parasitol.* 2019, 14, 387–393. [CrossRef] [PubMed]

63. Martínez-Valladares, M.; Rojo-Vázquez, F.A. Loop-mediated isothermal amplification (LAMP) assay for the diagnosis of fascioliosis in sheep and its application under field conditions. *Parasites Vectors* 2016, 9, 73. [CrossRef]

64. Arifin, M.I.; Höglund, J.; Novobilský, A. Comparison of molecular and conventional methods for the diagnosis of *Fasciola hepatica* infection in the field. *Vet. Parasitol.* 2016, 232, 8–11. [CrossRef]
65. Ai, L.; Li, C.; Elsheikha, H.M.; Hong, S.J.; Chen, J.X.; Chen, S.H.; Li, X.; Cai, X.Q.; Chen, M.X.; Zhu, X.Q. Rapid identification and differentiation of *Fasciola hepatica* and *Fasciola gigantica* by a loop-mediated isothermal amplification (LAMP) assay. *Vet. Parasitol.*** 2010, **174, 228–233. [CrossRef]

66. Arimatsu, Y.; Kaewkesb, S.; Lahab, T.; Sripa, B. Specific diagnosis of *Opisthorchis viverrini* using loop mediated isothermal amplification (LAMP) targeting parasite microsatellites. *Acta Trop.*** 2015, **141, 368–371. [CrossRef]

67. Le, T.H.; Nguyen, N.T.B.; Truong, N.H.; Van De, N. Development of mitochondrial loop-mediated isothermal amplification for detection of the small liver fluke *Opisthorchis viverrini* (Opisthorchiidae; Trematoda; Platyhelminthes). *J. Clin. Microbiol.*** 2012, **50, 1178–1184. [CrossRef]

68. Arimatsu, Y.; Kaewkesb, S.; Lahab, T.; Hongd, S.-J.; Sripa, B. Rapid detection of *Opisthorchis viverrini* copro-DNA using loop- mediated isothermal amplification (LAMP). *Parasitol. Int.*** 2012, **61, 178–182. [CrossRef] [PubMed]

69. Xunhui, Z.; Qingming, K.; Qunbo, T.; Haojie, D.; Lesheng, Z.; Di, L.; Jianzu, D.; Bin, Z.; Rui, C.; Tianping, W.; et al. DNA detection of *Paragonimus westermani*: Diagnostic validity of a new assay based on loop-mediated isothermal amplification (LAMP) combined with a lateral flow dipstick. *Acta Trop.*** 2019, **200, 105185. [CrossRef] [PubMed]

70. Chen, M.X.; Ai, L.; Zhang, R.L.; Xia, J.J.; Wang, K.; Chen, S.H.; Zhang, Y.N.; Xu, M.J.; Li, X.; Zhu, X.Q.; et al. Sensitive and rapid detection of *Paragonimus westermani* infection in humans and animals by loop-mediated isothermal amplification (LAMP). *Parasitol. Res.*** 2011, **108, 1193–1198. [CrossRef]

71. Chen, Y.; Wen, T.; Lai, D.; Wen, Y.; Wu, Z.; Yang, T.; Yu, X.; Hide, G.; Lun, Z. Development and evaluation of loop-mediated isothermal amplification (LAMP) for rapid detection of *Clonorchis sinensis* from its first intermediate hosts, freshwater snails. *Parasitology 2013, 140, 1377–1383. [CrossRef]

72. Botteau, E.; Clerinx, J. Human African Trypanosomiasis: Progress and stagnation. *Infect. Dis. Clin. N. Am.*** 2019, **33, 61–77. [CrossRef] [PubMed]

73. Lindner, A.K.; Lejon, V.; Chappuis, F.; Seixas, J.; Kazumba, L.; Barrett, M.P.; Mwamba, E.; Erphas, O.; Ak1, E.A.; Villanueva, G.; et al. New WHO guidelines for treatment of gambianse human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice. *Lancet. Infect. Dis.*** 2019, **3099, 1–9. [CrossRef]

74. WHO Neglected Tropical Diseases. Available online: https://www.who.int/neglected_diseases/diseases/en/ (accessed on 30 August 2019).

75. Akazue, P.I.; Ebiloma, G.U.; Ajibola, O.; Isaac, C.; Onyekwelue, K.; Ezeh, C.O.; Eze, A.A. Sustainable elimination (zero cases) of sleeping sickness: How far are we from achieving this goal? *Pathogens*** 2019, **8, 135. [CrossRef] [PubMed]

76. Büscher, P.; Cecchi, G.; Jamonneau, V.; Priotto, G. Human African trypanosomiasis. *Lancet 2017, 390, 2397–2409. [CrossRef]

77. Njiru, Z.K.; Mbae, C.K.; Mbiruugu, G.N. Loop-Mediated isothermal amplification test for *Trypanosoma gambiense* Group 1 with stem primers: A molecular xenomonitoring test for sleeping sickness. *J. Trop. Med.*** 2017, **2017, 8630708. [CrossRef]

78. Kassian, E.N.; Simuunza, M.C.; Silayo, R.S.; Moonga, L.; Ndebe, J.; Sugimoto, C.; Namangala, B. Prevalence and risk factors of bovine trypanosomosis in Kilwa district, Lindi region of southern Tanzania. *Vet. Parasitol. Reg. Stud. Reports*** 2017, **9, 1–5. [CrossRef]

79. Haji, I.J.; Sugimoto, C.; Kajino, K.; Malele, I.; Simukoko, H.; Chitambo, H.; Namangala, B. Determination of the prevalence of trypanosomasis species in cattle from Monduli district, northern Tanzania, by loop mediated isothermal amplification. *Trop. Anim. Health Prod.*** 2015, **47, 1139–1143. [CrossRef]

80. Ngotho, M.; Kagira, J.M.; Gachie, B.M.; Karanja, S.M.; Waema, M.W.; Maranga, D.N.; Maina, N.W. Loop mediated isothermal amplification for detection of *Trypanosoma brucei gambiense* in urine and saliva samples in nonhuman primate model. *Biomed. Res. Int.*** 2015, **2015, 867846. [CrossRef]

81. Mugas, C.M.; Katiti, D.; Boobo, A.; Lubeba, G.W.; Schallig, H.D.H.; Matovu, E. Comparison of nucleic acid sequence-based amplification and loop-mediated isothermal amplification for diagnosis of human African trypanosomiasis. *Diagn. Microbiol. Infect. Dis.*** 2014, **78, 144–148. [CrossRef]

82. Mitashi, P.; Hasker, E.; Ngoyi, D.M.; Pyana, P.P.; Lejon, V.; Van der Veken, W.; Lutumba, P.; Büscher, P.; Boelaert, M.; Deborggraeve, S. Diagnostic accuracy of loopamp *Trypanosoma brucei* detection kit for diagnosis of human african trypanosomiasis in clinical samples. *PLoS Negl. Trop. Dis.*** 2013, **7, 2504. [CrossRef]
83. Namangala, B.; Oparaocha, E.; Kajino, K.; Hayashida, K.; Moonga, L.; Inoue, N.; Suzuki, Y.; Sugimoto, C. Short report: Preliminary investigation of trypanosomosis in exotic dog breeds from Zambia’s Luangwa and Zambezi valleys using LAMP. *Am. J. Trop. Med. Hyg.* 2013, 89, 116–118. [CrossRef]

84. Namangala, B.; Hachaambwa, L.; Kajino, K.; Mweene, A.S.; Hayashida, K.; Simuunza, M.; Simukoko, H.; Choongo, K.; Chansa, P.; Lakhi, S.; et al. The use of Loop-mediated Isothermal Amplification (LAMP) to detect the re-emerging Human African Trypanosomiasis (HAT) in the Luangwa and Zambezi valleys. *Parasites Vectors* 2012, 5, 282. [CrossRef] [PubMed]

85. Njiru, Z.K. Rapid and sensitive detection of human African trypanosomiasis by loop-mediated isothermal amplification combined with a lateral-flow dipstick. *Diagn. Microbiol. Infect. Dis.* 2011, 69, 205–209. [CrossRef] [PubMed]

86. Njiru, Z.K.; Traub, R.; Ouma, J.O.; Enyaru, J.C.; Matovu, E. Detection of group 1 *Trypanosoma brucei gambiense* by loop-mediated isothermal amplification. *J. Clin. Microbiol.* 2011, 49, 1530–1536. [CrossRef]

87. Matovu, E.; Kuepfer, I.; Boobo, A.; Kibona, S.; Burri, C. Comparative detection of trypanosomal DNA by loop-mediated isothermal amplification and PCR from flinders technology associates cards spotted with patient blood. *J. Clin. Microbiol.* 2010, 48, 2087–2090. [CrossRef]

88. Njiru, Z.K.; Mikosza, A.S.J.; Armstrong, T.; Enyaru, J.C.; Ndung’u, J.M.; Thompson, A.R.C. Loop-mediated isothermal amplification (LAMP) method for rapid detection of *Trypanosoma brucei rhodesiense*. *PLoS Negl. Trop. Dis.* 2008, 2, e147. [CrossRef] [PubMed]

89. Kuboki, N.; Inoue, N.; Sakurai, T.; Di Cello, F.; Grab, D.J.; Suzuki, H.; Sugimoto, C.; Igarashi, I. Loop-Mediated Isothermal Amplification for detection of *Trypanosoma brucei gambiense*. *J. Clin. Microbiol.* 2003, 41, 5517–5524. [CrossRef]

90. Nayupe, S.F.; Simwela, N.V.; Kamanga, P.M.; Chisi, J.E.; Senga, E.; Musaya, J.; Maganga, E. The use of molecular technology to investigate trypanosome infections in tsetse flies at Liwonde Wild Life Reserve. *Malawi Med. J.* 2019, 31, 233–237. [CrossRef]

91. Ghobani, M.; Farhoudi, R. Leishmaniasis in humans: Drug or vaccine therapy? *Drug Des. Dev. Ther.* 2018, 12, 25–40. [CrossRef]

92. Taslimi, Y.; Zahedifard, F.; Rafati, S. Leishmaniasis in humans and various immunotherapeutic approaches. *Parasitology* 2018, 145, 497–507. [CrossRef]

93. Ibarra-Meneses, A.V.; Moreno, J.; Carrillo, E. New strategies and biomarkers for the control of visceral leishmaniasis. *Trends Parasitol.* 2020, 36, 29–38. [CrossRef] [PubMed]

94. Kaye, P.M.; Cruz, I.; Picado, A.; Van Bocxlaer, K.; Croft, S.L. Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs. *Semin. Immunopathol.* 2020. [CrossRef] [PubMed]

95. Sukphattanaudomchoke, C.; Siripattanapipong, S.; Thita, T.; Leelayoova, S.; Piyaraj, P.; Mungthin, M.; Ruang-areerate, T. Simplified closed tube loop mediated isothermal amplification (LAMP) assay for visual diagnosis of *Leishmania* infection. *Acta Trop.* 2020, 212, 105651. [CrossRef] [PubMed]

96. Silva Nunes Bezerra, G.; Barbosa Junior, W.L.; Cintra Leal, N.; De Medeiros, Z.M. Application of loop-mediated isothermal amplification (LAMP) assay for detection of *Leishmania infantum* strain from Brazil. *Iran. J. Parasitol.* 2020, 15, 155–157. [CrossRef]

97. De Lima Celeste, J.L.; Caldeira, R.L.; da Fonseca Pires, S.; Silveira, K.D.; Soares, R.P.; de Andrade, H.M. Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of *Leishmania amazonensis* in skin samples. *Exp. Parasitol.* 2019, 203, 23–29. [CrossRef] [PubMed]

98. De Avelar, D.M.; Carvalho, D.M.; Rabello, A. Development and clinical evaluation of loop-mediated isothermal amplification (LAMP) assay for the diagnosis of human visceral leishmaniasis in Brazil. *BioMed Res. Int.* 2019, 2019, 8240784. [CrossRef]

99. Chaouch, M.; Aoun, K.; Othman, S.B.; Abid, M.B.; Sghaier, I.B.; Bouratbine, A.; Abderrazak, S.B. Development and assessment of *Leishmania major* and *Leishmania tropica* specific loop-mediated isothermal amplification assays for the diagnosis of cutaneous leishmaniasis in Tunisia. *Am. J. Trop. Med. Hyg.* 2019, 101, 101–107. [CrossRef]

100. León, C.M.; Muñoz, M.; Tabares, J.H.; Hernandez, C.; Florez, C.; Ayala, M.S.; Ramírez, J.D. Analytical performance of a loop-mediated isothermal amplification assay for *Leishmania* DNA detection in sandflies and direct smears of patients with cutaneous leishmaniasis. *Am. J. Trop. Med. Hyg.* 2018, 98, 1325–1331. [CrossRef]
101. Imai, K.; Tarumoto, N.; Amo, K.; Takahashi, M.; Sakamoto, N.; Kosaka, A.; Kato, Y.; Mikita, K.; Sakai, J.; Murakami, T.; et al. Non-invasive diagnosis of cutaneous leishmaniasis by the direct boil loop-mediated isothermal amplification method and MinION™ nanopore sequencing. *Parasitol. Int.* 2018, 67, 34–37. [CrossRef]

102. Adams, E.R.; Schoone, G.; Versteeg, I.; Gomez, M.A.; Diro, E.; Mori, Y.; Perlee, D.; Downing, T.; Saravia, N.; Assaye, A.; et al. Development and evaluation of a novel loop-mediated isothermal amplification assay for diagnosis of cutaneous and visceral leishmaniasis. *J. Clin. Microbiol.* 2018, 56, 1–8. [CrossRef]

103. Verma, S.; Singh, R.; Sharma, V.; Bumb, R.A.; Negi, N.S.; Ramesh, V.; Salotra, P. Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of *Leishmania* infection. *BMC Infect. Dis.* 2017, 17, 1–9. [CrossRef] [PubMed]

104. Tiwananthagorn, S.; Kato, H.; Yeewa, R.; Muengpan, A.; Polseela, R.; Leelayoova, S. Comparison of LAMP and PCR for molecular mass screening of sand flies for *Leishmania martiniquensis* infection. *Mem. Inst. Oswaldo Cruz* 2017, 112, 100–107. [CrossRef] [PubMed]

105. Abbasi, I.; Kirstein, O.D.; Hallu, A.; Warburg, A. Optimization of loop-mediated isothermal amplification (LAMP) assays for the detection of *Leishmania* DNA in human blood samples. *Acta Trop.* 2016, 162, 20–26. [CrossRef] [PubMed]

106. Kothalawala, H.S.; Karunaweera, N.D. Loop-mediated isothermal amplification assay as a sensitive diagnostic tool for *Leishmania donovani* infections in Sri Lanka. *Ceylon Med. J.* 2016, 61, 68–70. [CrossRef] [PubMed]

107. Nzelu, C.O.; Cáceres, A.G.; Guerrero-Quincho, S.; Tineo-Villafuerte, E.; Rodríguez-Delfín, L.; Mimori, T.; Uezato, H.; Katakura, K.; Gomez, E.A.; Guevara, A.G.; et al. A rapid molecular diagnosis of cutaneous leishmaniasis by colorimetric malachite green-loop-mediated isothermal amplification (LAMP) combined with an FTA card as a direct sampling tool. *Acta Trop.* 2016, 153, 116–119. [CrossRef]

108. Gao, C.H.; Ding, D.; Wang, J.Y.; Steverding, D.; Wang, X.; Yang, Y.T.; Shi, F. Development of a LAMP assay for detection of *Leishmania infantum* infection in dogs using conjunctival swab samples. *Parasites Vectors* 2015, 8, 370. [CrossRef]

109. Sriworarat, C.; Phumee, A.; Munthtin, M.; Leelayoova, S.; Siriyasatien, P. Development of loop-mediated isothermal amplification (LAMP) for simple detection of *Leishmania* infection. *Parasites Vectors* 2015, 8, 591. [CrossRef]

110. Ghasemian, M.; Gharavi, M.J.; Akhlaghi, L.; Mohebali, M.; Meamar, A.R.; Aryan, E.; Oormazdi, H. Development and assessment of loop-mediated isothermal amplification (LAMP) assay for the diagnosis of human visceral leishmaniasis in Iran. *Iran. J. Parasitol.* 2014, 9, 50–59.

111. Mikita, K.; Maeda, T.; Yoshikawa, S.; Ono, T.; Miyahira, Y.; Kawana, A. The Direct Boil-LAMP method: A simple and rapid diagnostic method for cutaneous leishmaniasis. *Parasitol. Int.* 2014, 63, 785–789. [CrossRef]

112. Karani, M.; Sotiriadou, I.; Plutzier, J.; Karanis, P. Bench-scale experiments for the development of a unified loop-mediated isothermal amplification (LAMP) assay for the in vitro diagnosis of *Leishmania species’ promastigotes*. *Epidemiol. Infect.* 2014, 142, 1671–1677. [CrossRef]

113. Chaouch, M.; Mhadhibi, M.; Adams, E.R.; Schoone, G.J.; Limam, S.; Gharbi, Z.; Darghouth, M.A.; Guizani, I.; BenAbderrazak, S. Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of *Leishmania infantum* in canine leishmaniasis based on cysteine protease B genes. *Vet. Parasitol.* 2013, 198, 78–84. [CrossRef] [PubMed]

114. Verma, S.; Avishek, K.; Sharma, V.; Negi, N.S.; Ramesh, V.; Salotra, P. Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. *Diagn. Microbiol. Infect. Dis.* 2013, 75, 390–395. [CrossRef] [PubMed]

115. Khan, M.G.M.; Bhaskar, K.R.H.; Salam, M.A.; Akther, T.; Pluschke, G.; Mondal, D. Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of *Leishmania* DNA in buffy coat from visceral leishmaniasis patients. *Parasites Vectors* 2012, 5, 280. [CrossRef] [PubMed]

116. Adams, E.R.; Schoone, G.J.; Ageed, A.F.; El Safi, S.; Schallig, H.D.F.H. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of *Leishmania* parasites in clinical samples. *Am. J. Trop. Med. Hyg.* 2010, 82, 591–596. [CrossRef]

117. Takagi, H.; Itoh, M.; Islam, M.Z.; Razzak, A.; Ekram, A.R.M.S.; Hashighuchi, Y.; Noiri, E.; Kimura, E. Sensitive, specific, and rapid detection of *Leishmania donovani* DNA by loop-mediated isothermal amplification. *Am. J. Trop. Med. Hyg.* 2009, 81, 578–582. [CrossRef]
118. Ghodrati, M.; Spotin, A.; Hazratian, T.; Mahami-Oskouei, M.; Bordbar, A.; Ebrahimi, S.; Fallahi, S.; Parvizi, P. Diagnostic accuracy of loop-mediated isothermal amplification assay as a field molecular tool for rapid mass screening of old world *Leishmania* infections in sand flies and in vitro culture. *Iran. J. Parasitol.* 2017, 12, 506–515.

119. Hedtke, S.M.; Kuesel, A.C.; Crawford, K.E.; Graves, P.M.; Boussinesq, M.; Lau, C.L.; Boakye, D.A.; Grant, W.N. Genomic epidemiology in filarial nematodes: Transforming the basis for elimination program decisions. *Front. Genet.* 2020, 10, 1282. [CrossRef]

120. Molyneux, D.H. Advancing toward the elimination of lymphatic filariasis. *N. Engl. J. Med.* 2018, 379, 1871–1872. [CrossRef]

121. Lourens, G.B.; Ferrell, D.K. Lymphatic Filariasis. *Nurs. Clin. N. Am.* 2019, 54, 181–192. [CrossRef]

122. Dietrich, C.F.; Chaubal, N.; Hoerauf, A.; Kling, K.; Piontek, M.S.; Steffen, L.; Mand, S.; Dong, Y. Review of dancing parasites in lymphatic filariasis. *Ultrasound Int. Open* 2019, 5, E65–E74. [CrossRef]

123. Davis, E.L.; Reimer, L.J.; Pellis, L.; Hollingsworth, T.D. Evaluating the evidence for lymphatic filariasis elimination. *Trends Parasitol.* 2019, 35, 860–869. [CrossRef] [PubMed]

124. Srividya, A.; Subramanian, S.; Jambulingam, K.; Palaniappan, V.; Dinesh Raja, J. Mapping and monitoring for a lymphatic filariasis elimination program: A systematic review. *Res. Rep. Trop. Med.* 2019, 10, 43–90. [CrossRef] [PubMed]

125. Dorkenoo, M.A.; De Souza, D.K.; Apetogbo, Y.; Oboussoumi, K.; Yehadjji, D.; Tchalim, M.; Etassoli, S.; Koudou, B.; Ketho, G.K.; Sadahlon, Y.; et al. Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: No evidence for active transmission. *Parasites Vectors* 2018, 11, 1–9. [CrossRef] [PubMed]

126. Poole, C.B.; Alhassan, A.; Ouattara, N.; Diedougou, S.; Tchamou, S.; Zhang, Y.; Evans, T.C.; LaBarre, P.; Woji, S.; et al. Colorimetric tests for diagnosis of filarial infection and vector surveillance using noninstrumented nucleic acid loop-mediated isothermal amplification (NINA-LAMP). *PLoS ONE* 2017, 12, e0169011. [CrossRef]

127. De Souza, D.K.; Ansumana, R.; Ceesay, S.; Conteah, E.; Koudou, B.; Rebollo, M.; Koroma, J.; Boakye, D.A.; Bockarie, M.J. Impact of residual infections on *Anopheles*-transmitted *Wuchereria bancrofti* DNA in human blood and vector mosquitoes. *Parasitol. Int.* 2016, 60, 467–475. [CrossRef] [PubMed]

128. Gebrezgabiher, G.; Mekonnen, Z.; Yewhalaw, D.; Hailu, A. Reaching the last mile: Main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa. *Infect. Dis. Poverty* 2019, 8, 60. [CrossRef] [PubMed]

129. Tejada-Moya, E.; Golden, A.; Cantey, P.T. Diagnostics for onchocerciasis in the era of elimination. *Int. Health* 2018, 10, i20–i26. [CrossRef] [PubMed]
136. Alhassan, A.; Osei-Atweneboana, M.Y.; Kyeremeh, K.F.; Poole, C.B.; Li, Z.; Tettevi, E.; Tanner, N.A.; Carlow, C.K.S. Comparison of a new visual isothermal nucleic acid amplification test with PCR and skin snip analysis for diagnosis of onchocerciasis in humans. *Mol. Biochem. Parasitol.* 2016, 210, 10–12. [CrossRef]

137. Alhassan, A.; Makepeace, B.L.; Lacourse, E.J.; Osei-Atweneboana, M.Y.; Carlow, C.K.S. A simple isothermal DNA amplification method to screen black flies for Onchocerca volvulus infection. *PLoS ONE* 2014, 9, e108927. [CrossRef]

138. Thomas, C.; Coates, S.J.; Engelman, D.; Chosidow, O.; Chang, A.Y. Ectoparasites: Scabies. *J. Am. Acad. Dermatol.* 2020, 82, 533–548. [CrossRef]

139. Engelman, D.; Cantey, P.T.; Marks, M.; Solomon, A.W.; Chang, A.Y.; Chosidow, O.; Enbiale, W.; Engels, D.; Hay, R.J.; Hendrickx, D.; et al. The public health control of scabies: Priorities for research and action. *Lancet* 2019, 394, 81–92. [CrossRef]

140. Raffi, J.; Suresh, R.; Butler, D.C. Review of scabies in the elderly. *Dermatol. Ther. (Heidelb)* 2019, 9, 623–630. [CrossRef]

141. Fraser, T.A.; Carver, S.; Martin, A.M.; Mounsey, K.; Polkinghorne, A.; Jelocnik, M. A *Sarcoptes scabiei* specific isothermal amplification assay for detection of this important ectoparasite of wombats and other animals. *PeerJ* 2018, 6, e5291. [CrossRef]

142. Wells, B.; Burgess, S.T.G.; McNeilly, T.N.; Huntley, J.F.; Nisbet, A.J. Recent developments in the diagnosis of ectoparasite infections and disease through a better understanding of parasite biology and host responses. *Mol. Cell. Probes* 2012, 26, 47–53. [CrossRef]

143. Verjee, M.A. Schistosomiasis: Still a cause of significant morbidity and mortality. *Res. Rep. Trop. Med.* 2019, 10, 153–163. [CrossRef] [PubMed]

144. Anisuzzaman; Tsuji, N. Schistosomiasis and hookworm infection in humans: Disease burden, pathobiology and anthelmintic vaccines. *Parasitol. Int.* 2020, 75, 102051. [CrossRef] [PubMed]

145. Nelwan, M.L. Schistosomiasis: Life cycle, diagnosis, and control. *Curr. Ther. Res.* 2019, 101, 1–7. [CrossRef]

146. Price, M.; Cyrs, A.; Sikasunge, C.S.; Mwansa, J.; Lodh, N. Testing the infection prevalence of *Schistosoma mansoni* after mass drug administration by comparing sensitivity and specificity of species-specific repeat fragment amplification by PCR and loop-mediated isothermal amplification. *Am. J. Trop. Med. Hyg.* 2019, 101, 78–83. [CrossRef]

147. Verjee, M.A. Schistosomiasis: Still a cause of significant morbidity and mortality. *Res. Rep. Trop. Med.* 2019, 10, 153–163. [CrossRef] [PubMed]

148. Njiru, Z.K. Loop-mediated isothermal amplification technology: Towards point of care diagnostcs. *PLoS Negl. Trop. Dis.* 2012, 6, e1572. [CrossRef] [PubMed]

149. Ferrández-Soto, P.; Avendaño, C.; Sala-Vizcaíno, A.; Crego-Vicente, B.; Febrer-Sendra, B.; García-Bernalt Diego, J.; Oleaga, A.; López-Abán, J.; Vicente, B.; Patarroyo, M.A.; et al. Molecular markers for detecting *Schistosoma* species by loop-mediated isothermal amplification. *Dis. Markers* 2020, 2020. [CrossRef]

150. García-Bernalt Diego, J.; Ferrández-Soto, P.; Crego-Vicente, B.; Alonso-Castrillejo, S.; Febrer-Sendra, B.; Gómez-Sánchez, A.; Vicente, B.; López-Abán, J.; Muro, A. Progress in loop-mediated isothermal amplification assay for detection of *Schistosoma mansoni* DNA: Towards a ready-to-use test. *Sci. Rep.* 2019, 9, 14744. [CrossRef]

151. Price, M.; Cyrs, A.; Sikasunge, C.S.; Mwansa, J.; Lodh, N. Testing the infection prevalence of *Schistosoma mansoni* after mass drug administration by comparing sensitivity and specificity of species-specific repeat fragment amplification by PCR and loop-mediated isothermal amplification. *Am. J. Trop. Med. Hyg.* 2019, 101, 78–83. [CrossRef]

152. Ferrández-Soto, P.; Gandasegui, J.; Carranza, C.; Pérez-Arellano, J.L.; Crego-vicente, B.; García-Bernalt, J.; López-Albán, J.; Muro, A. Detection of *Schistosoma mansoni* derived DNA in human urine samples by loop-mediated isothermal amplification (LAMP). *PLoS ONE* 2019, 14, e0214125. [CrossRef]

153. Gandasegui, J.; Ferrández-Soto, P.; Dacal, E.; Rodriguez, E.; Saugar, J.M.; Yepes, E.; Aznar-Ruiz-de-Alegria, M.L.; Espasa, M.; Ninda, A.; Bocanegra, C.; et al. Field and laboratory comparative evaluation of a LAMP assay for the diagnosis of urogenital schistosomiasis in Cubal, Central Angola. *Trop. Med. Int. Health* 2018, 23, 992–1001. [CrossRef] [PubMed]

154. Mwangi, L.N.; Agola, E.L.; Muñgambi, R.M.; Shiraho, E.A.; Mkoji, G.M. Development and evaluation of a Loop-Mediated Isothermal Amplification Assay for diagnosis of *Schistosoma mansoni* infection in faecal samples. *J. Parasitol. Res.* 2018, 2018. [CrossRef] [PubMed]
155. Gandasegui, J.; Fernández-Soto, P.; Muro, A.; Simões Barbosa, C.; Lopes de Melo, F.; Loyo, R.; de Souza Gomes, E.C. A field survey using LAMP assay for detection of Schistosoma mansoni in a low-transmission area of schistosomiasis in Umbuzeiro, Brazil: Assessment in human and snail samples. *PLoS Negl. Trop. Dis.* 2018, 12, e006314. [CrossRef] [PubMed]

156. Gandasegui, J.; Fernández-soto, P.; Carranza-rodriguez, C. The Rapid-Heat LAMPellet method: A potential diagnostic method for human urogenital schistosomiasis. *PLoS Negl. Trop. Dis.* 2015, 9, e003963. [CrossRef]

157. Xu, J.; Guan, Z.; Zhao, B.; Wang, Y.; Cao, Y.; Zhang, H. DNA detection of *Schistosoma japonicum*: Diagnostic validity of a LAMP assay for low-intensity infection and effects of chemotherapy in humans. *PLoS Negl. Trop. Dis.* 2015, 9, e003668. [CrossRef]

158. Fernández-Soto, P.; Gandasegui, J.; Sánchez, A.; López-Abán, J.; Vicente, B.; Muro, A. A loop-mediated isothermal amplification (LAMP) Assay for early detection of *Schistosoma mansoni* in stool samples: A diagnostic approach in a murine model. *PLoS Negl. Trop. Dis.* 2014, 8, e3126. [CrossRef]

159. Xu, J.; Rong, R.; Zhang, H.Q.; Shi, C.J.; Zhu, X.Q.; Xia, C.M. Sensitive and rapid detection of *Schistosoma japonicum* DNA by loop-mediated isothermal amplification (LAMP). *Int. J. Parasitol.* 2010, 40, 327–331. [CrossRef]

160. Qin, Z.; Xu, J.; Feng, T.; Lv, S.; Qian, Y.; Zhang, L. Field evaluation of a loop-mediated isothermal amplification (LAMP) platform for the detection of *Schistosoma japonicum* infection in *Oncomelania hupensis* snails. *Trop. Med. Infect. Dis.* 2018, 3, 124. [CrossRef]

161. Lima, R.; Konovaloff, L.; Dos Santos, O. Use of molecular methods for the rapid mass detection of *Schistosoma mansoni* (Platyhelminthes: Trematoda) in *Biomphalaria* spp. (Gastropoda: Planorbidae). *J. Trop. Med.* 2017, 2017. [CrossRef]

162. Gandasegui, J.; Fernández-Soto, P.; Hernández-Goenaga, J.; López-Abán, J.; Vicente, B.; Muro, A. Biompha-LAMP: A new rapid Loop-Mediated Isothermal Amplification assay for detecting *Schistosoma mansoni* in *Biomphalaria glabrata* snail host. *PLoS Negl. Trop. Dis.* 2016, 10, e005225. [CrossRef]

163. Hamburger, J.; Abbasi, I.; Kariuki, C.; Wanjala, A.; Mzungu, E.; Muchiri, E.; King, C.H. Evaluation of loop-mediated isothermal amplification suitable for molecular monitoring of Schistosome-Infected snails in field laboratories. *Am. J. Trop. Med. Hyg.* 2013, 88, 344–351. [CrossRef] [PubMed]

164. Abbasi, I.; King, C.H.; Muchiri, E.M.; Hamburger, J. Detection of *Schistosoma mansoni* and *Schistosoma haematobium* DNA by loop-mediated isothermal amplification: Identification of infected snails from early prepatency. *Am. J. Trop. Med. Hyg.* 2010, 83, 427–432. [CrossRef] [PubMed]

165. Kumagai, T.; Furushima-Shimogawara, R.; Ohmae, H.; Wang, T.P.; Lu, S.; Chen, R.; Wen, L.; Ohta, N. Detection of early and single infections of *Schistosoma japonicum* in the intermediate host snail, *Oncomelania hupensis*, by PCR and loop-mediated isothermal amplification (LAMP) assay. *Am. J. Trop. Med. Hyg.* 2010, 83, 542–548. [CrossRef] [PubMed]

166. World Health Organization. *Guideline: Preventive Chemotherapy to Control Soil-Transmitted Helminth Infections in at-Risk Population Groups*; World Health Organization: Geneva, Switzerland, 2017; ISBN 9789241550116.

167. Tinkler, S.H. Preventive chemotherapy and anthelmintic resistance of soil-transmitted helminths – Can we learn nothing from veterinary medicine? *One Health* 2020, 9, 100106. [CrossRef] [PubMed]

168. Amoah, I.D.; Singh, G.; Stenström, T.A.; Reddy, P. Detection and quantification of soil-transmitted helminths in environmental samples: A review of current state-of-the-art and future perspectives. *Acta Trop.* 2017, 169, 187–201. [CrossRef] [PubMed]

169. Mutombo, P.N.; Man, N.W.; Nejsum, P.; Ricketson, R.; Gordon, C.A.; Robertson, G.; Clements, A.C.; Chacón-Forcena, N.; Nissapatorn, V.; Webster, J.P.; et al. Diagnosis and drug resistance of human soil-transmitted helminth infections: A public health perspective. *Math. Model. Neglected Trop. Dis.-Essent. Tools Control. Elimin.* Part B 2019, 104, 247–326.

170. Jourdan, P.M.; Lambert, P.H.L.; Fenwick, A.; Addiss, D.G. Soil-transmitted helminth infections. *Lancet* 2018, 391, 252–265. [CrossRef]

171. Savioli, L.; Albonico, M.; Daumerie, D.; Lo, N.C.; Stothard, J.R.; Assalou, S.; Tchuem Tchuenté, L.A.; Anderson, R.M. Review of the 2017 WHO guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. An opportunity lost in translation. *PLoS Negl. Trop. Dis.* 2018, 12, e0006296. [CrossRef] [PubMed]
172. Ngari, M.G.; Mwangi, I.N.; Njoroge, M.P.; Kinyua, J.; Osuna, F.A.; Kimeu, B.M.; Okanya, P.W.; Agola, E.L. Development and evaluation of a loop-mediated isothermal amplification (LAMP) diagnostic test for detection of whipworm, *Trichuris trichiura*, in faecal samples. *J. Helminthol.* 2020, 94, e142. [CrossRef]

173. Fernández-Soto, P.; Celis-Giraldo, C.T.; Collar-Fernández, C.; Gorgojo, O.; Camargo, M.; Muñoz, J.; Salas-Coronas, J.; Patarroyo, M.A.; Muro, A. Strong-LAMP assay based on a *Strongyloides* spp.-derived partial sequence in the 18S rRNA as potential biomarker for Strongyloidiasis diagnosis in human urine samples. *Dis. Markers* 2020, 2020. [CrossRef]

174. Rashwan, N.; Diawara, A.; Scott, M.E.; Prichard, R.K. Isothermal diagnostic assays for the detection of soil-transmitted helminths based on the SmartAmp2 method. *Parasites Vectors* 2017, 10, 496. [CrossRef] [PubMed]

175. Fernández-Soto, P.; Sánchez-Hernández, A.; Gandasegui, J.; Bajo Santos, C.; López-Abán, J.; Saugar, J.M.; Rodríguez, E.; Vicente, B.; Muro, A. Strong-LAMP: A LAMP assay for *Strongyloides* spp. detection in stool and urine samples. Towards the diagnosis of human Strongyloidiasis starting from a rodent model. *PLoS Negl. Trop. Dis.* 2016, 10, e0004836. [CrossRef]

176. Shiraho, E.A.; Eric, A.L.; Mwangi, I.N.; Maina, G.M.; Kinuthia, J.M.; Mutuku, M.W.; Mugambi, R.M.; Mwandi, J.M.; Mkoji, G.M. Development of a loop mediated isothermal amplification technique for the detection of hookworm (*Necator americanus*) infection in fecal samples. *Parasites Vectors* 2016, 9, 574. [CrossRef]

177. Okello, A.L.; Thomas, L.F. Human taeniasis: Current insights into prevention and management strategies in endemic countries. *Risk Manag. Healthcare Policy* 2017, 10, 107–116. [CrossRef]

178. Donadeu, M.; Fahrion, A.S.; Olliaro, P.L.; Abela-Ridder, B. Target product profiles for the diagnosis of *Taenia solium* taeniasis, neurocysticercosis and porcine cysticercosis. *PLoS Negl. Trop. Dis.* 2017, 11, e0005875. [CrossRef]

179. Gripper, L.B.; Welburn, S.C. Neurocysticercosis infection and disease–A review. *Acta Trop.* 2017, 166, 218–224. [CrossRef]

180. De Coster, T.; Van Damme, I.; Babauw, J.; Gabriël, S. Recent advancements in the control of *Taenia solium*: A systematic review. *Food Waterborne Parasitol.* 2018, 13, e00030. [CrossRef]

181. Nkouawa, A.; Sako, Y.; Okamoto, M.; Ito, A. Simple identification of human *Taenia* species by multiplex loop-mediated isothermal amplification in combination with dot enzyme-linked immunosorbent assay. *Am. J. Trop. Med. Hyg.* 2016, 94, 1318–1323. [CrossRef]

182. Nkouawa, A.; Sako, Y.; Nakao, M.; Yanagida, T.; Okamoto, M.; Giraudoux, P.; Raoul, F.; Nakaya, K.; et al. A loop-mediated isothermal amplification method for a differential identification of *Taenia* tapeworms from human: Application to a field survey. *Parasitol. Int.* 2012, 61, 723–725. [CrossRef] [PubMed]

183. Nkouawa, A.; Sako, Y.; Li, T.; Chen, X.; Nakao, M.; Yanagida, T.; Okamoto, M.; Giraudoux, P.; Raoul, F.; Nakaya, K.; et al. Evaluation of a loop-mediated isothermal amplification method using fecal specimens for differential detection of *Taenia* species from humans. *J. Clin. Microbiol.* 2010, 48, 3350–3352. [CrossRef] [PubMed]

184. Nkouawa, A.; Sako, Y.; Nakao, M.; Nakaya, K.; Ito, A. Loop-mediated isothermal amplification method for differentiation and rapid detection of *Taenia* species. *J. Clin. Microbiol.* 2009, 47, 168–174. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.